T HE COMPUTATIONAL PATIENT HAS DIABETES AND A COVID
A P REPRINT

arXiv:2006.06435v3 [cs.CE] 18 Jul 2020

Pietro Barbiero‚àó
Department of Computer Science and Technology, University of Cambridge, Cambridge, UK
pietro.barbiero@tutanota.com
Pietro Li√≥
Department of Computer Science and Technology, University of Cambridge, Cambridge, UK
pl219@cam.ac.uk

July 21, 2020

A BSTRACT
Medicine is moving from a curative discipline to a preventative discipline relying on personalised and
precise treatment plans. The complex and multi level pathophysiological patterns of most diseases
require a systemic medicine approach and are challenging current medical therapies. On the other
hand, computational medicine is a vibrant interdisciplinary field that could help move from an
organ-centered approach to a process-oriented approach. The ideal computational patient would
require an international interdisciplinary effort, of larger scientific and technological interdisciplinarity
than the Human Genome Project. When deployed, such a patient would have a profound impact
on how healthcare is delivered to patients. Here we present a computational patient model that
integrates, refines and extends recent mechanistic or phenomenological models of cardiovascular,
RAS and diabetic processes. Our aim is twofold: analyse the modularity and composability of
the model-building blocks of the computational patient and to study the dynamical properties of
well-being and disease states in a broader functional context. We present results from a number of
experiments among which we characterise the dynamic impact of COVID-19 and type-2 diabetes
(T2D) on cardiovascular and inflammation conditions. We tested these experiments under different
exercise, meal and drug regimens. We report results showing the striking importance of transient
dynamical responses to acute state conditions and we provide guidelines for system design principles
for the inter-relationship between modules and components in systemic medicine. Finally this initial
computational Patient can be used as a toolbox for further modifications and extensions.
Keywords computational Patient ¬∑ computational Medicine ¬∑ Systems medicine ¬∑ COVID ¬∑ T2D Diabete ¬∑
Cardiovascular model ¬∑ Blood Pressure model

1

Introduction

Computational medicine is increasingly effective to understand and predict complex physiological and pathological
conditions in scenarios of single organ disease to comorbidities. Both mechanistic and phenomenological models are
important aspects of computational medicine. When we formulate hypotheses on the mechanisms (usually involving
molecules) underlying the behaviour of the various endpoints of a process, we could build a mechanistic model; when
we formulate hypotheses based on the empirical observations of a phenomenon, we could build a phenomenological
model. Most models are actually a combination of the two and there are certainly overlaps between phenomenological
modeling, statistical and machine learning. Mechanistic and phenomenological modeling aim at reproducing the main
features of a real system with the minimum number of parameters and still providing explainability, interpretability
‚àó

Use footnote for providing further information about author (webpage, alternative address)‚Äînot for acknowledging funding
agencies.

A PREPRINT - J ULY 21, 2020

and often causality. The objective is to gain a better understanding of how each of the different components of a
biomedical system contribute to the overall process, its emerging properties and the causality relation of the occurred
events. A mechanistic and phenomenological model could be formulated using ordinary or partial differential equations
[1], stochastic processes [2], logic [3] or in terms of a tailor-made syntax which could facilitate formal analysis and
verification [4, 5]. The dedicated modeler may introduce a series of models of a process at different scales, from
the molecular level to the whole body level, or describing processes occurring in different organs under the same
disease conditions. Although there is growing awareness of long range communications in the body - for instance the
communicome [6] or the gut-brain axis [7], the integration of various models in order to capture the behavior at systems
medicine level has not been pursued so much. Examples of such multi level communication are given by the extensive
network of comorbidities. Comorbidity is the term used to address diseases, often chronic ones, co-occurring in the
same individual. An important challenge is the homogenisation of models across multiple spatial and time scales, which
requires cell-level models to be systematically scaled up to the tissue/organ level, and related asymptotic techniques for
the analysis of multiple timescale problems, such as those arising in processes communications. The cardiovascular
system is usually described using a cardio-centric view. As an example, the heart is considered as the only pump in the
system. Other pumps are actually the skeletal muscle which returns blood from the periphery to the central circulation.
Another pump is embedded in the elastic arteries that use elastic properties to propel the blood forward. This system
is subtly coupled with the cardiovascular-associated nervous system and the blood pressure control which include
the regulated inputs from many other organs, most notably lungs, kidney and pancreas [8]. Therefore, the concept of
cardiovascular disease could be reformulated as a more complexly connected system and disease landscape, perhaps
inclusive of comorbidities, which could allow a better patient stratification and prognosis and consequently better drug
discovery.
In particular, infectious diseases are good examples of the need of inter-organ and inter-process modeling approaches as
a pathogen fitness may require colonising different body environments. A current example is given by the COVID-19
pandemia. Diabetes is a frequent comorbidity; the Coronado study has shown that 29% of the people with T2D
infected with COVID-19 were intubated and 10.6% die in one week [9]. The mortality statistics show that fighting
the COVID-19 pandemia requires a focus on comorbidities. Many of the older patients who become severely ill have
evidence of underlying illness such as cardiovascular disease, kidney disease, T2D or tumours [10]. They make the
largest percentage of patient who cannot breathe on their own because of severe pneumonia and acute respiratory
distress syndrome and require intubation: about a quarter of intubated coronavirus patients die within the first few
weeks of treatment [11].

2

Objectives
Objective 1
Introduce modular and composable paradigms for the design of computational patients.

In Sec. 3 we propose a modular approach for the design of personalised computational physiology systems. The
complexity underlying multifactorial diseases requires the introduction of multi-scale, extensible and adaptable models
where modular principles are used to break organism complexity and composable criteria to select, link and combine
different components in a hierarchical fashion.
Objective 2
Show how our approach may help in disclosing cascade effects of comorbidities.
In Sec. 6 we illustrate a concrete example where personalised comorbid conditions‚Äô dynamics can be modeled and
analysed using our framework. We focus on developing an integrated computational system modeling ripple effects of
comorbidities on blood pressure regulation. To this end, in Sec. 4 we revised the physiological background required
to understand the main underlying biological processes involved in this mechanism. Building upon previous studies,
we devise a customisable computational patient in the form of a computational tool composed of extended versions
of three publicly available mathematical models describing the circulatory system [12], type-2 diabetes [13], and
renin-angiotensin system (RAS) [14], one of the main pathways regulating inflammatory response and blood pressure.
Respiratory failure is a key feature of severe COVID-19 and a critical driver of mortality; 10.6% of all diabetic patients
hospitalised die within one week. Hence, in Sec. 5 we propose a set of equations modeling the impact of type-2 diabetes
on blood vessels‚Äô stiffness and the influence of additional external factors which can be personalised according to
patient‚Äôs characteristics and lifestyle habits. We introduce a variety of such elements describing the repercussions on
2

A PREPRINT - J ULY 21, 2020

blood pressures caused by ageing, type-2 diabetes, viral infections like COVID-19, ACE inhibitor treatments, meals,
and physical exercise.

3
3.1

Computational tool
From integration to modularity and composability

In recent decades, the interest and the scientific effort in developing integrated quantitative and descriptive computational
systems modeling physiological dynamics has rapidly grown. By 1997 the Physiome Project [15] and the EuroPhysiome
Initiative [16] have actively devised and organised rich collections of mathematical models describing the functional
behavior of components of living organisms, such as organs, cell systems, biochemical reactions, or endocrine systems.
Such a modular approach has been primarily used to reduce complexity by deconvolvingthe human physiome into
elementary subunits. Indeed, each computational module can be seen as a standalone biological entity describing
one of the structures, processes, or pathways of the whole organism. Yet, modeling physiological interactions, multiscale signalling, and comorbidities requires the combination of multiple components to build more sophisticated
computational systems. Several approaches have been proposed where different mathematical models have been
integrated into a single system in order to describe synergistic effects and emerging phenomena [12]. Despite being
widely used and accepted, such system design paradigm often requires an overwhelming amount of work in merging
multiple systems together, and in tuning and validating the integrated model. Besides, technological advances in
computer science in the last twenty years have dramatically changed coding languages and paradigms. Hence, different
research groups have developed their computational systems on many different coding platforms, frameworks, and
libraries, including general-purpose languages like MatLab, Java, Python, C, but also special-purpose ones like JSim.
The variety of implementation platforms combined with the mathematical effort required to merge many different
systems is in conflict with the urgent need of user-friendly, extensible, and adaptable system design paradigms where
components can be selected and assembled in various combinations to satisfy specific requirements. Personalised
medicine requires the introduction of novel system design paradigms where modules break organism complexity and
composable criteria are used to select and combine different components. Instead of merging, tuning, and validating
the whole integrated system, each module could be tuned and validated independently. Composable criteria may
allow researchers to primarily focus on multi-scale signalling between modules. Tuning and validation may apply
just on inter-module signals which will make the overall system independent on module-specific implementation
characteristics.
3.2

Module design and personalisation

In order to move towards this modern system design, each module can be seen as a black box processing signals coming
from other modules and combining them with external subject-specific parameters in order to provide a set of responses
(see Fig. 2). Subject-specific parameters may be derived from on-line clinically relevant measures, such as heart
pressure or insulin levels, or from the Electronic Health Record [18, 19], such as morbidities, treatments, or clinical
examinations. Such elements can be used to personalise the module taking into account unique subject characteristics.
Incoming signals from other components may impact some of the variables and parameters of the module, but cannot
change its architecture. Finally, the outputs provided by each module can be simultaneously used as inputs for other
components or tracked as clinically relevant latent variables.
3.3

Usage guidelines

The computational system has been designed in order to allow for three levels of user interaction. computational
scientists and coders may take advantage of publicly available code by improving or forking the GitHub repository [21].
The repository structure has a modular design so that new packages can be included independently. Each new package
should correspond to a new mathematical model. Multiple packages can be combined together in order to generate
more complex computational systems. Medical practitioners and biologists with some Python experience may just
download the repository, reproduce the simulations on their computers, or modify some parameters. In order to make
the computational tool available for clinicians and practitioners without coding skills, the whole computational system
has been incorporated into a website with a graphical user interface. Users may profit from this user-friendly interaction
as the system can be customised in many different ways creating multiple scenarios by modifying several parameters,
including patient-specific characteristics and constants related to models‚Äô interactions.
3

A PREPRINT - J ULY 21, 2020

(A)
module A

(B)
(C)
death
trajectories

module B

PHASE SPACE
PARAMETER SPACE

healthy
neighbourhood

module C

Figure 1: In modular systems several modules can be used independently to model physiological processes, disregarding
their mutual relationships (A). The selection and combination of different components in a hierarchical fashion by
means of composable criteria allows a better exploration of the parameter space (B). The actual interpenetration of
multiple systems can be achieved by modeling the dynamics of their mutual relationships providing further information
on the underlying phenomena (C). Such deeper exploration of the parameter space enhances the evaluation of initial
conditions and trajectories in the phase space (right).
Figure design inspired by [17].

3.4

Numerical methods

All the necessary code for the experiments has been implemented in Python 3, relying upon open-source libraries.
The mathematical equations described in Sec. 5 form a set of ODE systems and algebraic equations that have been
sequentially solved using the LSODA integration method [22, 23] provided by the function solve_ivp included into the
scipy Python package [24]. All the experiments have been run on the same machine: Intel R CoreTM i7-8750H 6-Core
Processor at 2.20 GHz equipped with 8 GiB RAM.

4

Physiological background

The objective of our model is showing how the combined effects of comorbidities may lead to severe cardiovascular
and pulmonary conditions. To this aim, we include in our model some of the main factors, pathways, and morbidities
affecting blood pressure with a focus on pulmonary vessels, i.e. oxygenation, arterial stiffness, diabetes, RAS, and
COVID-19. In this section we revise the physiological background of the elements involved in our computational
system.
4.1

The link between hypertension, oxygenation and blood pressure variability

Exposure to chronic hypoxia causes pulmonary hypertension and pulmonary vascular remodelling [25]. COVID results
in decreased oxygen that can result in impaired functioning of the heart and brain and cause difficulty with breathing
(a PaO2 reading below 80 mm Hg or a pulse ox (SpO2) below 95 percent is considered low). When the left side of
the heart cannot pump blood out to the body normally, blood backs up in the lungs and increases blood pressure there.
The COVID-19 virus can activate the blood clotting pathway. Studies have reported that 30% of COVID-19 patients
showed signs of blood clots in their lungs which means that a blood clot that has traveled to the lung. One of the
recommendations is to give a low dose of heparin, which prevents clot formation or tissue plasminogen activator (tPA),
which helps to dissolve blood clots [26, 27]. High blood pressure can damage the arteries by making them less elastic,
which decreases the flow of blood and oxygen and leads to heart disease. The relationship between blood pressure and
stroke recurrence is controversial. Recent researches stress that both high mean value of blood pressure and blood
4

A PREPRINT - J ULY 21, 2020
MODULAR PARADIGM

INTEGRATION PARADIGM
LUNGS

LUNGS

HEART
SIST. CIRC.

CIRCULATORY
SYSTEM
BRAIN

KIDNEYS
KIDNEYS
CELLS

RAS +
CIRCULATORY
SYSTEM

RENINANGIOTENSIN
SYSTEM

HEART

COMPOSABLE PARADIGM
CIRCULATORY SYSTEM

CELLS
LUNGS

HEART

SISTEMIC
CIRCULATION

BRAIN

BRAIN
RENIN-ANGIOTENSIN SYSTEM
KIDNEYS

SISTEMIC
CIRCULATION

CELLS
subject-specific parameters
inter-module signals

Figure 2: Modular paradigms are used to break organism complexity into simpler components which can be analysed
and modeled independently (left). Integrating different modules requires an overwhelming amount of work in merging
one after the other multiple systems together, and in tuning and validating the final model (top right). Composable
criteria favor a dynamic and adaptable selection of different components allowing researchers to primarily focus on
modeling the relationships between modules (bottom right).
Illustrations adapted from The Sourcebook of medical illustration [20].

pressure variability (particularly long term) are important. Although some variation in blood pressure throughout the
day is normal, higher variation in blood pressure is associated with a higher risk of cardiovascular disease and all-cause
mortality [28, 29]. In young people here is a an increased blood supply response to hypoxia which could vanish in
elderly with high blood pressure. This compromised response may be caused by the high blood pressure-induced
impairment in the function of the blood vessels [30].
4.1.1

Arterial stiffness

Arterial stiffness is a broad term used to describe loss of arterial compliance and changes in vessel wall properties.
Both arterial stiffness and high blood pressure variability can be indicators of cardiovascular risk [31, 32, 33, 34, 35].
Ageing increases arterial stiffness and that increased arterial stiffness gives rise to increased blood pressure variability
[36]. Although arterial stiffness can be assessed using a variety of techniques, carotid‚Äìfemoral pulse wave velocity
is the preferred measure. It has been shown that increased arterial stiffness is an early risk marker for developing
type-2 diabetes [37], and a causal association between T2D and increased arterial stiffness has been proved on a large
cohort of patients [38, 39]: 1 standard deviation increase in T2D is associated with 6% higher risk in increased arterial
stiffness; see also [40]. Arterial stiffness is also related to Inflammageing which is a chronic low-grade inflammation
that develops with advanced age. It is believed to accelerate the process of biological ageing and to worsen many
age-related diseases [41, 42]. In particular inflammatory cytokines (which may be activated by angiotensinII) result in
increased arterial stiffness; on the contrary reductions in inflammation (for example due to anti-inflammatory cytokines),
exercise reduce arterial stiffness [43, 44].
4.2

The renin-angiotensin system and SARS-CoV-2

The renin-angiotensin system (RAS) is a hormone system regulating vasoconstriction and inflammatory response [45].
The key regulator of the RAS is the peptide hormone Angiotensin II (ANG-II) generated by the angiotensin-converting
enzyme (ACE) which cleaves the decapeptide Angiotensin I (ANG-I), or proangiotensin. ANG-II exerts its biological
functions through two G-protein-coupled receptors, the ANG-II receptor type 1 receptor (AT1R) and ANG-II receptor
type-2 receptor (AT2R), and the heptapeptide Angiotensin (1-7) (ANG-(1-7)) which binds and activates the G-protein5

A PREPRINT - J ULY 21, 2020

coupled Mas receptor (MAS). ANG-(1-7) can be generated both by the angiotensin-converting enzime 2 (ACE2) from
ANG-II, or by the neutral endopeptidase enzyme (NEP) from ANG-I. The three G-protein-coupled receptors (AT1R,
AT2R, and MAS) are the main factors helping the body to carry out the role of ANG-II in regulating blood pressure
over the course of the day [46][47]. On one side, AT1R stimulates vasoconstriction, hypertension, and inflammatory
response. The effect of AT1R is counterbalanced by MAS, promoting vasodilation, hypotension, and vasoprotection.
The role of AT2R is currently debated [48]. Under normal physiologic conditions, AT2R counteracts most effects of
AT1R. However, recent developments have shown how its vasodilatory effects were not associated with significant
reduction in blood pressure [49]. In the kidney, AT2R stimulation produced natriuresis, increased renal blood flow,
and reduced tissue inflammation [50, 51, 52]. External factors impacting the RAS include: glucose concentration,
ACE inhibitor treatements, and viral infections binding to ACE2, such as SARS-CoV-2. Glucose concentration has
a direct impact both on AT1R and ACE activity. A high glucose concentration may determine chronic hypertensive
conditions. Therefore, hypertensive treatments usually include ACE inhibitor drugs which are used to compensate the
overproduction of ANG-II and AT1R [53]. Viral infections such as COVID-19 may also have a negative impact on
RAS, as the virus binds to ACE2 in order to gain entry into the host cell, impairing the activity of ACE2 in generating
ANG-(1-7) by hydrolyzing ANG-II [54].

SARS-CoV

SARS-CoV

Vasoconstriction
Hypertension
Inflammation

Eqs. ùüèùüî ‚àí ùüèùüñ

Eqs. ùüî ‚àí ùüèùüì

GLUCOSE

AT1R
Eq. ùüë

ACEi

Eq. ùüì

ALVEOLI

Eqs. ùüñùüè ‚àí ùüóùüí

ANG II
ACE2

PULMONARY CIRCULATION

Eqs. ùüêùüí ‚àí ùüíùüí, ùüóùüì ‚àí ùüèùüèùüé

Eq. ùüè

ACE2

Eq. ùüê

ACE

ANG I
Eqs. ùüèùüó ‚àí ùüêùüë

NEP

ANG-(1-7)

Eqs. ùüèùüèùüè ‚àí ùüèùüèùüì

BARORECEPTORS

MAS

SYSTEMIC CIRCULATION

Vasodilation
Vasoprotection
Hypotension?

Eqs. ùüíùüì ‚àí ùüñùüé

Eqs. ùüèùüî ‚àí ùüèùüñ

KIDNEYS

Figure 3: Schematic representation of the circulatory system composed of heart, pulmonary circulation, systemic
circulation, and baroreceptors (left). External factors affecting the renin-angiotensin system (ACEi and SARS-CoV-2)
are shown in violet (right).
Illustrations adapted from The Sourcebook of medical illustration [20].

5

Mathematical model of diabetic computational patients

In this section we present a concrete example describing a set of mathematical models that can be used to model a
computational patient.
We focus on modeling a diabetic computational patient by combining four modules: RAS 5.1, diabetic 5.2, circulatory
5.3, and stiffness 5.4 models. Fig. 3 shows a schematic representation of the computational system. The computational
patient can be customised in two different ways. First, the system has been designed in order to be personalised using
patient-specific values for some parameters such as age, glucose levels, arterial blood pressure, presence of comorbidities
or treatments (see Table 1). Should the physiological analysis require the inclusion of additional conditions, new
modules can be included and composed according to patient‚Äôs needs.
6

A PREPRINT - J ULY 21, 2020

Table 1: computational patients‚Äô customisable parameters.
Class

Clinical record

Comorbidities

Treatments

Lifestyle

5.1

Parameter

Description

Values

Units

A

Age

20 ‚àí 70

years

G

Blood glucose levels

100 ‚àí 200

ml/dl

ABP

Arterial blood pressure (from clinical records, e.g. [12])

80 ‚àí 120

mmHg

[D]

Vitamin D concentration

20 ‚àí 40

ng/mL

inf ection

Presence/absence of SARS-CoV-2 infection

{True, False}

-

renal

Normal/impaired renal function

{True, False}

-

drug

Presence/absence of ACEi treatments

{True, False}

-

d

ACEi dosage (Benazepril)

0‚àí5

mg

nd

Number of daily drug administrations

{0, 1}

-

[heparin]0

Initial heparin dosage by intra venous injection

5000 ‚àí 10000

U/mL

tw

Daily workout starting time

6 p.m.

-

zw

Daily workout intensity (burned calories)

200

kcal

tm

Daily meals‚Äô starting time

{8 a.m. , 12 p.m. , 8 p.m.}

-

gm

Daily meals‚Äô glycemic load

{4, 42, 42}

-

sm

Daily meals‚Äô carbohydrate serving

{50, 100, 100}

g

Renin-angiotensin system and blood pressure regulation

The biochemical reaction network used to model the renin-angiotensin system is shown in Fig. 3. External factors
include hypertension treatments and viral infections binding to ACE2, such as SARS-CoV-2. Hypertension drugs
usually target ACE inhibiting ANG II production. ANG II promotes vasoconstriction, hypertension, inflammation,
and fibrosis by activating AT1R. Therefore, reducing ANG II production with ACE inhibitors increases vasodilation
and vasoprotection effects stimulated by AT2R and ANG-(1-7). On the other hand, SARS-CoV-2 infections reduce
ANG-(1-7) and ANG-(1-9) production rate, by binding to ACE2 in order to gain entry into the host cell. Hence,
vasoprotection effects promoted by ANG-(1-7) decline, possibly leading to hypertension and inflammatory response.
5.1.1

Pharmacokinetic model

Pharmacokinetic (PK) models are used to describe drug absorption and excretion dynamics. Equation 1 describes
the analytical solution of a single-compartment pharmacokinetic model with first-order absorption and first-order
elimination rates after oral administration [55]. The equation has been used to model ACE inhibitors‚Äô dynamics and
their effects on the RAS. A uniform dose size d at constant time intervals œÑ has been assumed [56]:
ka F
[Drug]n (t ) = d
(ka ‚àí ke )V
0

1 ‚àí exp(‚àínke œÑ )
1 ‚àí exp(‚àínka œÑ )
exp ‚àíke t0 ‚àí
exp ‚àíka t0
1 ‚àí ke œÑ
1 ‚àí ka œÑ

!
(1)

where [Drug]n (t0 ) is the drug concentration after the n-th dose, t0 = t(n ‚àí 1)œÑ is the time after the n-th dose, ka and
ke are the absorption and elimination rates respectively, F is the absorbed fraction of the drug, and V the volume of
distribution.
Pharmacokinetic parameters have been reported in table 3.
5.1.2

Pharmacodynamic model

Pharmacodynamic models are used to illustrate the effects of drug treatments on the body. The pharmacodynamic
model used to describe local RAS dynamics has been derived from [57, 14] (see Eqs. 16-20). The original model has
been extended with four additional equations (Eqs. 2-5). The variation of [AN G17], [AT 1R] and [AT 2R] have been
included as their dynamics can be useful in understanding how RAS regulates blood pressure [58]. The concentration
of ANG-(1-7) depends on the activity of two enzymes, NEP and ACE2, cleaving ANG-I and ANG-II respectively.
[AT 1R] and [AT 2R] rather depend on [AN GII] and on glucose concentration G.
7

A PREPRINT - J ULY 21, 2020

d[AN G17]
dt

NEP-catalyzed conversion of ANG I

ACE2-catalyzed conversion of ANG II

z
}|
{
kN EP [AN GI]

z
}|
{
kACE2 [AN GII]

=

+

d[AT 1R]
dt

=

}|
aAT 1R G + bAT 1R



‚àí

ln 2

}|

hAN G17

{

[AN G17]

(2)

degradation

ANG-II bounds

z


degradation

z

}|
{
{ z
ln 2
[AN GII] ‚àí
[AT 1R]
hAT 1R

(3)

degradation

d[AT 2R]
dt

=

}|
{
z
ANG-II bounds
z
}|
{
ln 2
kAT 2R [AN GII] ‚àí
[AT 2R]
hAT 2R

(4)

The dynamics of ACE2 activity (kACE2 ) has been introduced as an indicator of SARS-CoV-2 infectivity [54]:
dkACE2
=
dt



sV [AN GII] ‚àí eAI kACE2
0

during SARS-CoV-2 infection
otherwise

(5)

where sV represents the severity of the viral infection and eAI the efficiency of anti-inflammatory pathways. A higher
concentration of [AN GII] may also induce cells to produce more ACE2, thus increasing its activity [54] and enhancing
viral entry. Hence ACE-inhibitor treatments may have a protective role as they reduce ACE activity lowering ANG-II
levels (see Fig. 3).
Pharmacodynamic parameters and initial conditions have been reported in table 4.
5.2

Adding comorbidities: type-2 Diabetes

type-2 diabetes is a metabolic disease whose progression and severity is caused by increasing failure of insulinproduction due to beta cell death.
There are complex multifactorial links between diabetes and cardiovascular disease [59, 60, 61, 62]. The main
pathophysiology cornerstone is a state of chronic, low-level inflammation. This immune activation may facilitate both
the insurgence and progression of insulin resistance in diabetic and pre-diabetic states and increases their cardiovascular
risk. An extension of a model from Topp and collaborators (Eqs. 6-9) combines insuline resistance, functional Œ≤-cell
mass dynamics with glucose dynamics and insulin dynamics [13]. The insulin and glucose dynamics are faster than the
beta cell dynamics. Mild hyperglycaemia leads to increasing beta cell numbers, but above a threshold of 250mg/dL
blood glucose, beta cell death is greater than cell division. Additional terms (not shown) include and non-functional beta
cells (Œ≤f and Œ≤nf ), activated macrophage, pathogenic T cells, insulin resistance, mTOR levels and beta cell antigenic
protein concentrations [63]. The distinction between beta cells into functioning and non-functioning cells allows to
take into account for the reduction and exhaustion of insulin produced by the beta cells. Although the preliminary
outcomes of the DIRECT study suggests that beta cells can be restored to normal function through the removal of
excess fat in the cells [64, 65], we have not taken into account the recovery of the pancreatic function. Inflammation
is key in diabetes, and the interaction between inflammation and metabolism can be considered a key homeostatic
mechanism [66]. The model considers both the effect of exercise and dietary [67]. This model was analysed using
sensitivity analysis and investigation to determine its properties (not shown). Sensitivity analyses are commonly used in
inverse modelling to determine how significant each parameter is to the output variables of the system. A local analysis
describes the sensitivity relative to point estimates of the parameters whereas a global analysis examines the entire
parameter distribution.
effect of insulin resistance


dG
= R0 ‚àí G EG0 +
dt

z

}| {
I
SI
IR + i

diet



workouts

z }| { z }| {
+ R1 Hm (t) ‚àí R2 Hw (t)

(6)

effect of glucose

z }| {
dI
Œ≤f G2
=œÉ
‚àíkI
dt
Œ± + G2
8

(7)

A PREPRINT - J ULY 21, 2020

dŒ≤f
= ‚àír0 + r1 G ‚àí r2 G2 Œ≤f
dt

(8)

pro-inflammatory cytokines

dIR
= ‚àíi0 IR +
dt

z }| {
mCyt

+qI

(9)

where G is the glucose concentration, I is Insulin concentration, Œ≤f functioning Œ≤-cells, IR insulin resistance, and Cyt
is the concentration of pro-inflammatory cytokines [68, 69, 70]. Hm and Hw are two step functions describing glucose
intake during meals and glucose consumption during workouts respectively:
Hm =

X

gm,i sm,i Itm,i (1+‚àÜm ) (t)

(10)

i

Hw =

X

zw,i Itw,i (1+‚àÜw ) (t)

(11)

i

where gm is the glycemic load, sm the carbohydrate serving, and tm the meal starting time; zw the number of burned
calories and tw the workout starting time; Itm,i (1+‚àÜm ) (t) and Itw,i (1+‚àÜw ) (t) are indicator functions.
Here we consider progressive alteration of arterial stiffness and hypertension in diabetic patients. It is noteworthy
that low chronic inflammation related to metabolic active abdominal obesity (abnormal secretion of adipokines and
cytokines like TNF-alfa and interferon) and the impaired immune-response to infection (abnormal cytokine profile
and T-cell and macrophage activation) cause an increased risk of severe COVID-19. Diabetic patients are frailer with
respect to the normal population when considering COVID-19 multi-organ and multi-process disruption.
5.3

Circulatory system model

Circulatory system models are used to describe blood flow, volume, and pressure dynamics. Equations 21-117 illustrate
a simplified open-loop cardiovascular model composed of five components: heart (21-41), systemic circulation (42-76),
pulmonary circulation (77-90), coronary circulation (91-106), and baroreceptors (107-111). Equations have been derived
from the open-loop circulatory model proposed in [12]. The heart model is composed of four sections (chambers)
corresponding to right atrium, right ventricle, left atrium, and left ventricle. Each chamber is modeled as a bellows
pump comprised of a one-way valve (pulmonary, tricuspid, mitral, and aortic) and a time-varying elastance (Eq. 28)
controlling blood outflow [71, 72]. Blood inflow is passive. The systemic circulation has been modeled with seven
vascular segments: proximal aorta, distal aorta, arteries, arterioles, capillaries, veins, and the vena cava. Each vessel
has been designed using a resistance element reflecting the impact on blood flow reduction and a compliance element
indicating the tendency of arteries and veins to stretch in response to pressure. High-frequency effects caused by wave
reflections at great arterial bifurcations (distal and proximal aorta) are modeled with inertance elements. Arterioles,
veins and vena cava have unique nonlinear PV relationships as described in [73] (see Eqs. 50-52, 54, and 42). The
pulmonary circulation is composed of five vascular segments: proximal and distal pulmonary artery, small arteries,
capillaries, and veins. Wave reflections in the proximal and distal pulmonary arteries are modeled with inertance
elements. The coronary circulation model consists of four segments: epicardial and intramiocardial arteries, coronary
capillaries, and coronary veins. Following [12], large and small artery and vein segments proposed in [74] have been
condensed into intramiocardial arteries and coronary veins, respectively. Baroreceptors are special sensory neurons that
are excited by a stretch in the carotid sinus and aortic arch vessels. Their feedback is processed by the brain in order
to maintain proper blood pressure. Baroreceptors‚Äô firing frequency to the brain has been modeled as a second-order
response to the aortic pressure change [75, 73]. The second-order differential equation has been rewritten into two first
order equations in order to make it compatible with common Python solvers (Eqs. 109 and 110).
Circulatory system parameters and initial conditions have been reported in table 7.
5.4

Stiffness model

The complexity underlying multifactorial diseases requires the introduction of computational systems representing
multi-organ and inter-process communication. To this aim, we propose a mathematical model describing the impact of
comorbidities on the circulatory system. Several factors influencing blood pressure and arterial stiffness have been
modeled including: diabetes, renal impairments, viral infections, lifestyle and ageing.
9

A PREPRINT - J ULY 21, 2020

Ageing affects the circulatory system in multiple ways. Baroreceptors‚Äô feedback and pathways to the heart‚Äôs pacemaker
system decrease their efficiency over time. Heart muscle cells tend to degenerate and its walls get thicker slowing down
the time the heart takes to fill with blood increasing pressure on the vessels. Additionally, blood vessels show a decrease
in performance, since arteries tend to narrow and become more rigid.
Glucose concentration affects the renin-angiotensin-aldosterone pathway as it controls the concentration and activity
of Renin, ACE, and AT1R. AT1R activity is strongly related to vasoconstriction, hypertension, and inflammatory
response. Hence, arterial stiffness gets even worse increasing the risks of clogged arteries and strokes. Besides,
SARS-CoV-2 strongly bind to ACE2 decreasing its availability and impacting downstream RAS pathways regulating
blood pressure. Lower levels of available ACE2 reduce the concentration of ANG-(1-7), the endogenous ligand for the
G protein-coupled receptor MAS, a receptor associated with cardiac, renal, and cerebral protective responses. Hence,
vasoprotection and hypotension feedbacks deteriorate increasing inflammatory response and pressure on blood vessels.
The combined effect of comorbidities and ageing factors on arterial stiffness and inflammation may lead to critical
circulatory conditions and fibrosis. High glucose concentrations strengthen RAS hypertension feedbacks and lower
blood vessels‚Äô lumen, especially on capillaries, arterioles, and venules. By affecting blood pressure regulation pathways,
SARS-CoV-2 infections may impair vasoprotection regulation by the RAS endangering the whole circulatory system
with disruptive repercussions among the elderly. The combination of all such factors may lead to acute diseases such
as thrombophlebitis, cardiomyopathy, myocardial infarction, pulmonary embolism, heart failure, and eventually to
patients‚Äô death.
The diabetic model (Sec. 5.2) accounts both for hyperglycemic conditions and lifestyle habits. After lunch and
dinner, glucose concentration in blood vessels peaks, while it is scaled down by insulin or physical exercise. The RAS
model (Sec. 5.1) has been used to simulate peptides‚Äô and drug concentration dynamics taking into account glucose
concentration, ACE inhibitor treatments, renal conditions, and viral infections binding to ACE2 (such as COVID-19).
Abnormal ACE2 activity (kACE2 ‚àí kACE2,0 ) has been assumed as proportional to SARS-CoV-2 infectivity (see Eq. 5).
ACEi or ARB treatments could also increase ACE2 abundance and thus enhance viral entry [54]. In case of severe renal
conditions, only a fraction of drug diacid is expelled before the subsequent administration (see Eq. 1 and Fig. 4). The
drug surplus left inside the body may reinforce inflammation. Overall, the inflammatory response has been modeled as
a function of all such contributions:
drug treatment

viral infection

dIR
dt

glucose

z
}|
{ z }| { z}|{
= kSARS (kACE2 ‚àí kACE2,0 ) + kD [Drug] + kG G ‚àí

anti-inflammatory response

z }| {
kef f IR

(12)

where kSARS represents SARS-CoV-2 affinity with ACE2, kD the inflammation rate due to ACEi surplus, kG the
inflammation rate due to glucose surplus, and kef f the anti-inflammatory response rate.
One of the main processes associated with arterial stiffness occurring during ageing is DNA methylation, consisting in
the addition of methyl groups to the DNA molecule which may modify the activity of a DNA segment without changing
the sequence. DNA methylation has been modeled as a linear function of the age A [31]:
Œ±M ET = Œ≤0 ‚àí Œ≤1 A

Œ≤0,1 ‚â• 0

(13)

As a result, blood vessels‚Äô compliance parameters have been reduced by a factor accounting for the combined effect of
inflammation (Eq. 12) and ageing (Eq. 13):
stiffness

z

}|
{

IR 
b
Ci
Ci = Œ±M ET 1 ‚àí
100

(14)

bi is the reduced compliance. The
where Ci is the compliance of the blood vessel i for a young healthy individual and C
circulatory model (Sec. 5.3) has been used to simulate blood pressure dynamics in critical vessels where blood pressure
spikes may lead to acute diseases.
5.5

Extending the model to COVID-19 treatments

One of the main issues related to COVID-19 is blood clotting. Studies have reported that 30% of COVID-19 patients
showed signs of blood clots in their lungs. One of the recommendations is to give a low dose of heparin, which prevents
clot formation or tissue plasminogen activator (tPA), which helps to dissolve blood clots [26, 27]. Besides, several
10

A PREPRINT - J ULY 21, 2020

observational studies and clinical trials reported that vitamin D supplementation reduced the risk of influenza and
inflammation by raising its blood concentrations above 40-60 ng/mL (100-150 nmol/L) [76, 77, 78, 79]. Hence, we
extended our model by taking into account such preliminary COVID-19 treatments. In fact, both heparin and vitamin
D have an indirect impact on blood pressure by making blood less dense, reducing clotting formation, and lowering
inflammation. We modeled the impact of such treatments by including additional terms on blood pressure inside the
cardiovascular model:
pbi = pi ‚àí Œ≤h [heparin] ‚àí Œ≤D ([D] ‚àí [D]0 )

(15)

where [heparin] is the heparin dosage and [D] the vitamin D concentration.

6

Experiments

The models presented in Section 5 have been solved to analyze the effects of comorbidities like diabetes, renal
impairment, and viral infections affecting the circulatory system. Table 2 reports the set of experimental conditions
that have been analysed. Five computational patients have been created corresponding to different physiological states.
These scenarios have been further stratified by the age of the computational patient, given that arterial stiffness has been
modeled as a function of the increased DNA methylation during ageing. Drug concentrations (Fig. 4), inflammation
levels, and blood pressure dynamics in lung vessels (Fig. 5) in comorbid conditions have been compared to the dynamics
obtained in healthy states or using ACE inhibitor treatments.
Table 2: computational patients‚Äô conditions used for the simulations. The diabetic and the RAS models do not depend
on patient‚Äôs age. Lifestyle habits have been set as three meals and one light workout session in the afternoon for all
patients.
Label

Age

Description

H

20

Healthy individual

D

-

Diabetic individual

R

-

Individual with renal impairment

C+T

70

Individual with comorbid conditions (diabetes + renal impairment) treated with ACEi

V

70

Individual with COVID-19

C+V

70

Individual with comorbid conditions and COVID-19

C+V+T

70

Individual with comorbid conditions and COVID-19 treated with ACEi

C+V+3T

70

Individual with comorbidities and COVID-19 treated with ACEi, heparin, and vitamin D

The RAS model has been simulated for constant glucose cases using the daily glucose peak predicted by the diabetic
model right after the main meals. Glucose concentration ranged between the extremes of normal glucose at 6 ‚àí 7
mmol/L (corresponding to 108 ‚àí 125 ml/dl) and high glucose at 10 ‚àí 11 mmol/L (corresponding to 180 ‚àí 200
ml/dl) based on experimental studies [80, 81, 82]. The time window of the RAS simulations has been set to five
days, corresponding to five daily ACEi administrations [53]. The simulation results have been used to compute
arterial stiffness and to reduce compliance parameters of blood vessels in the open-loop circulatory model. In the
following simulations the arterial blood pressure (ABP) signal used in [12] has been used instead of personalised
clinical measurements.
Fig. 4 shows the dynamics of the concentration of ACEi and glucose-insulin dynamics over the first five days of
treatment. Due to renal impairment, the computational patient was not able to expel the drug dose before the next
administration. The inflammatory response and the corresponding blood pressure dynamics in lungs‚Äô vessels are shown
in Fig. 5. Comorbid conditions tend to increase blood pressure variability in all scenarios. However, as arterial stiffness
grows with the age of the computational patient, the variability increases as well, possibly leading to irreversible
deterioration of blood vessels‚Äô walls. ACEi treatments may help in reducing inflammation levels, but may not be
sufficient to recover healthy blood pressures. One of the most serious effects illustrated by simulations consists of
an increased mean value of blood pressure and blood pressure variability especially on small pulmonary vessels and
capillaries (see Fig. 5), increasing the risk of clogged arteries, fibrosis, and strokes. Besides, experimental results
shows how fluctuations of variables over time may change and present different shapes especially on small vessels.
11

A PREPRINT - J ULY 21, 2020

60

glucose [ml/dl]

drug diacid [ng/ml]

80

H
R

40
20
0

0

1

2
3
time [days]

4

225
200
175
150
125
100
75

5

blood glucose

H
D
metabolised glucose
5

10

15
20
25
insulin [mU/ml]

30

35

Figure 4: Drug concentration for healthy individuals and patients with renal impairments (left). Glucose metabolised
by insulin in healthy and diabetic individuals (right).
In computational patients with comorbidities blood pressure dynamics in pulmonary capillaries exhibit higher mean
values and variability, but beat frequencies can be observed as well.

inflammation

50

capillaries [mmHg]

60
H
C+T
V
C+V
C+V+T

40
30
20
10

45
40
35
30
25
20
15
10

0

1

2
3
time [days]

4

H
C+T
V
C+V
C+V+T

5

15

20

25 30
artery [mmHg]

35

40

25
capillaries [mmHg]

artery [mmHg]

0

20
18
16
14
12
10
8

H
C+T
V
C+V
C+V+T

1

2

3
time [sec]

4

H
C+T
V
C+V
C+V+T

20
15
10
1

2

3
time [sec]

4

Figure 5: Inflammation scores (top-left, see Eq. 12), the corresponding lungs‚Äô pressures phase space (top-right) and
dynamics over time (bottom)
6.1

COVID-19

The COVID-19 mortality statistics underline the relevance of deeper analysis on multi-factorial diseases in fighting
the pandemic [9]. Underlying morbidities such as cardiovascular disease, kidney disease, T2D or tumours have been
observed in patients with severe infection, especially among the elderly [10]. By affecting blood pressure regulation
pathways, SARS-CoV-2 infections may impair vasoprotection regulation endangering the whole circulatory system
with severe repercussions. By taking advantage of our composable framework, experimental results offer an overview
on how the combination of multiple diseases with SARS-CoV-2 may lead to acute conditions. Fig. 5 clearly shows how
the computational patient with comorbidities and SARS-CoV-2 has higher risk of pulmonary vessels‚Äô deterioration.
The combined effect of heparin and vitamin D can help in reducing blood pressure mean by making the blood more fluid.
However, they do not affect blood pressure variability determined by vessels‚Äô rigidity. Hence, the risk in developing
12

A PREPRINT - J ULY 21, 2020

cardiovascular diseases related to blood pressure variability may still be high despite treatments. Notably the results of
our experiments agree with hypotheses suggesting that healthy blood vessels protect children from serious effects of
COVID-19.

capillaries [mmHg]

It is noteworthy that autopsy-based findings have demonstrated a variety of damages caused by COVID-19 infection,
among which extensive coagulopathy, acquired thrombophilia and endothelial cell death [83]. Here we consider the
sole effect on blood pressure.

20
18
16
14
12
10
8
6

C+V
C+V+T
H
C+V+3T

10

15

20 25 30
artery [mmHg]

35

40

Figure 6: Comparing blood pressure effects of COVID-19 treatments in pulmonary vessels.

7

Discussion

The modularity and composability of different available mechanistic and phenomenological models presents the challenge to define a mathematical framework connecting different systems‚Äô descriptions, their dynamics, and constraints.
Let‚Äôs imagine to put together a model based on ODEs and a model in terms of a discrete space discrete time Markov
chain. This has then to be done in the light of behavioral properties that can be sets of trajectories or measures on
the trajectory space (typically those learned from data with statistical methods). Cell-level models (using ODEs,
delay differential equations, DDE, or agents) need to be systematically scaled up to the tissue level; for the multiple
timescale problems, the challenge is to obtain a model order reduction, i.e. to abandon high dimensional bioengineering
systems in favour of simpler effective mathematical models. The tissue level could be modeled using PDE or cellular
Potts model which may provide better representation for detailed and heterogeneous cell-cell, cell-tissue, cell-matrix
interaction cases. Integrative models, could be made by single scale models, describing the biological process at
different characteristic space-time scales, and scale bridging models, which define how the component models are
coupled to each other. While at the tissue level, physical quantities usually vary across space and time, in a continuous
fashion, and can be thus represented using systems of PDE [84].
7.1

Emerging properties of variances from model composability

Many physiological variables have a circadian trend; sometimes also a seasonal one. For example blood pressure
decreases during sleep and shows a sharp uprise at the time of awakening. This early morning variation is often
concurrent with an increase of acute myocardial infarction, sudden cardiac death, and stroke [85]. Common clinical
parameters such as diastolic and systolic blood pressure, heart patterns, blood cell counts are usually evaluated as
averages. Little importance is given to higher moments such as variances during the day or during a longer interval of
time. The lack of continuous measures for most of the quantities has generated a medical practice that disregard of
unobserved or partially observed data. Some authors identified a disease and age-related loss of complex variability in
multiple physiologic processes including cardiovascular control, pulsatile hormone release, and ECG data [86, 87]. Our
composable model reveals interesting patterns, particularly fluctuations in blood pressure, particularly during COVID
acute infection when the diabetic model is coupled with the RAS and the cardiovascular models. We believe that the
use of extensive models could enable to understand concurrent patterns of alteration in different districts.
13

A PREPRINT - J ULY 21, 2020

7.2

How such computational patient model could be deployed and further developed

computational Patient will benefit from using machine learning and data analysis of large amount of data such for
instance that obtained from UK Biobank as modeling will have a truly catalytic effect in synergy with machine learning.
The computational patient model requires adequate artificial intelligence support to generate diagnosis and validate its
correctness. A decision-making process could be based on the development of a personalised statistics of changes in
health, end-stage disease, signs and symptoms (CHESS, [88]). This ideally would develop through monitoring of the
individualized response to therapeutic interventions, in addition to changes in risk profile. One aspect is a dedicated
CHESS scale based on all the variables and observable considered considered by the model(s) [88, 89]. It will act as
a personalised patient simulator and will draw temporal trajectories of disease and comorbidities progression. The
trajectories will change with drug regimes, medical intervention, and lifestyle changes.
Any data used will be anonymises or de-identified using ad hoc software (see for instance [90]) and we will follow the
FAIR principle (Findable, Accessible, Interoperable, Reusable) and the GRPD regulation. One meaningful approach to
extract useful indication is to use a clinical decision support system which incorporates medical experience, research
results and personal judgement [91]. We believe the computational patient models to be in a research only state and
therefore we do not make further integrations.
The future foreseen is that AI will assist our health and disease conditions in a more effective way than nowadays: a
medical check up will be supported by well-tuned artificial intelligence and patient-based modeling . At the clinical
level, computer-aided therapies and treatments will develop into intervention strategies undertaken under acute disease
conditions or due to external factors (infections) to contrast cascade effects. In non acute states, predictive inference
will propose prevention plans for comorbidity management, particularly in presence of multiple therapies.
Therefore this approach is meaningful in perspective of a computational medicine characterised by a close coupling
between bioinformatics, clinical measures and modeling prediction and perhaps remote patient monitoring.

8

Conclusion

computational scientists and bioengineers‚Äô vision is a framework of methods and technologies that, once established,
will make it possible to investigate the human body as a whole. It calls for a total transformation in the way healthcare
currently works and is delivered to patients. Underpinning this transformation is substantial technological innovation
with a requirement for deeper trans-disciplinary research, improved IT infrastructure, better communication, large
volumes of high quality data and machine learning and modeling tools. Machine learning could be automatised (i.e.
autoML) and models should be modular so to be organised to answer specific and personalised medical questions.
Simulations are increasingly regarded as valuable tools in a number of aspects of medical practice including lifestyle
changes, surgical planning and medical interventions. The idea is that cross-modality data is obtained for the patient
and machine learning techniques estimate parameters to be input into modeling framework. We believe that a deeper
understanding and practice of modeling in medicine will produce better investigation of complex biological processes,
and even new ideas and better feedback into medicine. Finally, computational models are cheap and this will make
possible to predict drugs interaction and to make better use of generic drugs. In this sense the personalised model will
become a product associated with the drug.
8.1

Disclaimer

The computational tool has not been validated and should not be used for clinical purposes.
To enable code reuse, the Python code for the mathematical models including parameter values and documentation is
freely available under Apache 2.0 Public License from a GitHub repository [21]. Unless required by applicable law or
agreed to in writing, software is distributed on an "as is" basis, without warranties or conditions of any kind, either
express or implied.

9

Acknowledgement

The authors have received funding from the European Union‚Äôs Horizon 2020 research and innovation programme under
grant agreement No 848077. We thank Gianluca Ascolani, Rachel Clark, Annalisa Occhipinti, Stefan Stojanovic, Emma
Rocheteau, Jacob Deasy, Alberto Giannoni, Alberto Tonda, and Elisabetta Zara for suggestions.
14

A PREPRINT - J ULY 21, 2020

References
[1] Gianluca Ascolani, Annalisa Occhipinti, and Pietro Li√≤. Modelling circulating tumour cells for personalised
survival prediction in metastatic breast cancer. PLOS Computational Biology, 11(5):e1004199, May 2015.
[2] E. Giampieri, D. Remondini, L. de Oliveira, G. Castellani, and P. Li√≥. Stochastic analysis of a miRNA‚Äìprotein
toggle switch. Molecular BioSystems, 7(10):2796, 2011.
[3] Jo√´lle Despeyroux, Amy Felty, Pietro Li√≤, and Carlos Olarte. A logical framework for modelling breast cancer
progression. In Molecular Logic and Computational Synthetic Biology, pages 121‚Äì141. Springer International
Publishing, 2019.
[4] Ezio Bartocci and Pietro Li√≥. Computational modeling, formal analysis, and tools for systems biology. PLoS
computational biology, 12(1), 2016.
[5] Ezio Bartocci, Pietro Li√≤, Emanuela Merelli, and Nicola Paoletti. Multiple verification in complex biological
systems: the bone remodelling case study. In Transactions on Computational Systems Biology XIV, pages 53‚Äì76.
Springer, 2012.
[6] Sandip Ray, Markus Britschgi, Charles Herbert, Yoshiko Takeda-Uchimura, Adam Boxer, Kaj Blennow, Leah F
Friedman, Douglas R Galasko, Marek Jutel, Anna Karydas, et al. Classification and prediction of clinical
alzheimer‚Äôs diagnosis based on plasma signaling proteins. Nature medicine, 13(11):1359‚Äì1362, 2007.
[7] Nobuyuki Sudo, Yoichi Chida, Yuji Aiba, Junko Sonoda, Naomi Oyama, Xiao-Nian Yu, Chiharu Kubo, and
Yasuhiro Koga. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress
response in mice. The Journal of Physiology, 558(1):263‚Äì275, June 2004.
[8] Sirisha Achanta, Jonathan Gorky, Clara Leung, Alison Moss, Shaina Robbins, Leonard Eisenman, Jin Chen, Susan
Tappan, Maci Heal, Navid Farahani, Todd Huffman, Steve England, Zixi (Jack) Cheng, Rajanikanth Vadigepalli,
and James S. Schwaber. A comprehensive integrated anatomical and molecular atlas of rat intrinsic cardiac
nervous system. iScience, page 101140, May 2020.
[9] Bertrand Cariou, , Samy Hadjadj, Matthieu Wargny, Matthieu Pichelin, Abdallah Al-Salameh, Ingrid Allix,
Coralie Amadou, Gw√©na√´lle Arnault, Florence Baudoux, Bernard Bauduceau, Sophie Borot, Muriel BourgeonGhittori, Olivier Bourron, David Boutoille, France Cazenave-Roblot, Claude Chaumeil, Emmanuel Cosson,
Sandrine Coudol, Patrice Darmon, Emmanuel Disse, Am√©lie Ducet-Boiffard, B√©n√©dicte Gaborit, Michael Joubert,
V√©ronique Kerlan, Bruno Laviolle, Lucien Marchand, Laurent Meyer, Louis Potier, Ga√´tan Prevost, Jean-Pierre
Riveline, Ren√© Robert, Pierre-Jean Saulnier, Ariane Sultan, Jean-Fran√ßois Th√©baut, Charles Thivolet, Blandine
Tramunt, Camille Vatier, Ronan Roussel, Jean-Fran√ßois Gautier, and Pierre Gourdy. Phenotypic characteristics
and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia, May 2020.
[10] Tianbing Wang, Zhe Du, Fengxue Zhu, Zhaolong Cao, Youzhong An, Yan Gao, and Baoguo Jiang. Comorbidities
and multi-organ injuries in the treatment of COVID-19. The Lancet, 395(10228):e52, March 2020.
[11] Safiya Richardson, Jamie S. Hirsch, Mangala Narasimhan, James M. Crawford, Thomas McGinn, Karina W.
Davidson, Douglas P. Barnaby, Lance B. Becker, John D. Chelico, Stuart L. Cohen, Jennifer Cookingham, Kevin
Coppa, Michael A. Diefenbach, Andrew J. Dominello, Joan Duer-Hefele, Louise Falzon, Jordan Gitlin, Negin
Hajizadeh, Tiffany G. Harvin, David A. Hirschwerk, Eun Ji Kim, Zachary M. Kozel, Lyndonna M. Marrast,
Jazmin N. Mogavero, Gabrielle A. Osorio, Michael Qiu, and Theodoros P. Zanos and. Presenting characteristics,
comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new york city area. JAMA,
April 2020.
[12] Maxwell Lewis Neal and James B Bassingthwaighte. Subject-specific model estimation of cardiac output and
blood volume during hemorrhage. Cardiovascular engineering, 7(3):97‚Äì120, 2007.
[13] B Topp, K Promislow, G Devries, RM Miuraa, and DT Finegood. A Model of Œ≤‚àícell mass, insulin and glucose
kinetics: Pathways to diabetes. J. theor. Biol., 206:605‚Äì609, 2000. doi:10.1006/jtbi.2000.2150.
[14] Minu R Pilvankar, Hui Ling Yong, and Ashlee N Ford Versypt. A glucose-dependent pharmacokinetic/pharmacodynamic model of ace inhibition in kidney cells. Processes, 7(3):131, 2019.
[15] Peter Hunter, Peter Robbins, and Denis Noble. The iups human physiome project. Pfl√ºgers Archiv, 445(1):1‚Äì9,
2002.
[16] S Van Sint Jan, M Viceconti, and G Clapworthy. The europhysiome: towards an infrastructure for a more
integrated research. Journal of biomechanics, 40:S282, 2007.
[17] Jeremy Gunawardena. Models in systems biology: the parameter problem and the meanings of robustness.
Elements of Computational Systems Biology. New Jersey: John Wiley and Sons, pages 21‚Äì48, 2010.
15

A PREPRINT - J ULY 21, 2020

[18] Dipak Kalra. Electronic health record standards. Yearbook of medical informatics, 15(01):136‚Äì144, 2006.
[19] Nir Menachemi and Taleah H Collum. Benefits and drawbacks of electronic health record systems. Risk
management and healthcare policy, 4:47, 2011.
[20] Peter Cull. The Sourcebook of medical illustration: over 900 anatomical, medical, and scientific illustrations
available for general re-use and adaptation free of normal copyright restrictions. Parthenon Publishing, 1989.
[21] Pietro Barbiero and Pietro Li√≤. https://github.com/pietrobarbiero/computational-patient.
[22] Alan C Hindmarsh. Odepack, a systematized collection of ode solvers. Scientific computing, pages 55‚Äì64, 1983.
[23] Linda Petzold. Automatic selection of methods for solving stiff and nonstiff systems of ordinary differential
equations. SIAM journal on scientific and statistical computing, 4(1):136‚Äì148, 1983.
[24] Fernando P√©rez, HP Langtangen, and R LeVeque. Python for scientific computing. In SIAM Conference on
Computational Science and Engineering, volume 42, 2009.
[25] Katherine Howell, Henry Ooi, Rob Preston, and Paul McLoughlin. Structural basis of hypoxic pulmonary
hypertension: the modifying effect of chronic hypercapnia. Experimental Physiology, 89(1):66‚Äì72, December
2003.
[26] Celestino Sardu, Jessica Gambardella, Marco Bruno Morelli, Xujun Wang, Raffaele Marfella, and Gaetano Santulli.
Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? a comprehensive
evaluation of clinical and basic evidence. Journal of Clinical Medicine, 9(5):1417, May 2020.
[27] Ning Tang, Huan Bai, Xing Chen, Jiale Gong, Dengju Li, and Ziyong Sun. Anticoagulant treatment is associated
with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis
and Haemostasis, 18(5):1094‚Äì1099, April 2020.
[28] Bum Joon Kim, Sun U. Kwon, Dalia Wajsbrot, Jaseong Koo, Jong Moo Park, and Barrett W. Jeffers. Relationship
of inter-individual blood pressure variability and the risk for recurrent stroke. Journal of the American Heart
Association, 7(24), December 2018.
[29] Y Tao, J Xu, B Song, X Xie, H Gu, Q Liu, L Zhao, Y Wang, Y Xu, and Y Wang. Short-term blood pressure
variability and long-term blood pressure variability: which one is a reliable predictor for recurrent stroke. Journal
of Human Hypertension, 31(9):568‚Äì573, April 2017.
[30] Igor A. Fernandes, Marcos P. Rocha, Monique O. Campos, Jo√£o D. Mattos, Daniel E. Mansur, Helena N. M. Rocha,
Paulo A. C. Terra, Vin√≠cius P. Garcia, Nat√°lia G. Rocha, Niels H. Secher, and Antonio C. L. N√≥brega. Reduced
arterial vasodilatation in response to hypoxia impairs cerebral and peripheral oxygen delivery in hypertensive men.
The Journal of Physiology, 596(7):1167‚Äì1179, February 2018.
[31] Wen Wen, Rong Luo, Xiaojing Tang, Lan Tang, Hunter X. Huang, Xiaoyan Wen, Shan Hu, and Bin Peng.
Age-related progression of arterial stiffness and its elevated positive association with blood pressure in healthy
people. Atherosclerosis, 238(1):147‚Äì152, January 2015.
[32] Michael F. O‚ÄôRourke and Wilmer W. Nichols. Aortic diameter, aortic stiffness, and wave reflection increase with
age and isolated systolic hypertension. Hypertension, 45(4):652‚Äì658, April 2005.
[33] Gary F. Mitchell, Shih-Jen Hwang, Ramachandran S. Vasan, Martin G. Larson, Michael J. Pencina, Naomi M.
Hamburg, Joseph A. Vita, Daniel Levy, and Emelia J. Benjamin. Arterial stiffness and cardiovascular events.
Circulation, 121(4):505‚Äì511, February 2010.
[34] Sripal Bangalore, David J. Maron, Sean M. O‚ÄôBrien, Jerome L. Fleg, Evgeny I. Kretov, Carlo Briguori, Upendra
Kaul, Harmony R. Reynolds, Tomasz Mazurek, Mandeep S. Sidhu, Jeffrey S. Berger, Roy O. Mathew, Olga
Bockeria, Samuel Broderick, Radoslaw Pracon, Charles A. Herzog, Zhen Huang, Gregg W. Stone, William E.
Boden, Jonathan D. Newman, Ziad A. Ali, Daniel B. Mark, John A. Spertus, Karen P. Alexander, Bernard R.
Chaitman, Glenn M. Chertow, and Judith S. Hochman. Management of coronary disease in patients with advanced
kidney disease. New England Journal of Medicine, 382(17):1608‚Äì1618, April 2020.
[35] Donald Clark, Stephen J. Nicholls, Julie St John, Mohamed B. Elshazly, Haitham M. Ahmed, Haitham Khraishah,
Steven E. Nissen, and Rishi Puri. Visit-to-visit blood pressure variability, coronary atheroma progression, and
clinical outcomes. JAMA Cardiology, 4(5):437, May 2019.
[36] Tokuhisa Uejima, , Frank D. Dunstan, Eloisa Arbustini, Krystyna ≈Åoboz-GrudzienÃÅ, Alun D. Hughes, Scipione Carerj, Valentina Favalli, Francesco Antonini-Canterin, Olga Vriz, Dragos Vinereanu, Jose L. Zamorano, Bogdan A.
Popescu, Arturo Evangelista, Patrizio Lancellotti, Georges Lefth√©riotis, Michaela Kozakova, Carlo Palombo, and
Alan G. Fraser. Age-specific reference values for carotid arterial stiffness estimated by ultrasonic wall tracking.
Journal of Human Hypertension, 34(3):214‚Äì222, August 2019.
16

A PREPRINT - J ULY 21, 2020

[37] Iram Faqir Muhammad, Yan Born√©, Gerd √ñstling, Cecilia Kennb√§ck, Mikael Gotts√§ter, Margaretha Persson,
Peter M. Nilsson, and Gunnar Engstr√∂m. Arterial stiffness and incidence of diabetes: A population-based cohort
study. Diabetes Care, 40(12):1739‚Äì1745, September 2017.
[38] Min Xu, Ya Huang, Lan Xie, Kui Peng, Lin Ding, Lin Lin, Po Wang, Mingli Hao, Yuhong Chen, Yimin Sun, Lu Qi,
Weiqing Wang, Guang Ning, and Yufang Bi. Diabetes and risk of arterial stiffness: A mendelian randomization
analysis. Diabetes, 65(6):1731‚Äì1740, March 2016.
[39] Wei Gan, Fiona Bragg, Robin G. Walters, Iona Y. Millwood, Kuang Lin, Yiping Chen, Yu Guo, Julien Vaucher,
Zheng Bian, Derrick Bennett, Jun Lv, Canqing Yu, Anubha Mahajan, Robert J. Clarke, Liming Li, Michael V.
Holmes, Mark I. McCarthy, and Zhengming Chen. Genetic predisposition to type 2 diabetes and risk of subclinical
atherosclerosis and cardiovascular diseases among 160, 000 chinese adults. Diabetes, 68(11):2155‚Äì2164, August
2019.
[40] James M. Eales, Simon P.R. Romaine, Fadi J. Charchar, and Maciej Tomaszewski. A multi-omics glimpse into
the biology of arterial stiffness. Journal of Hypertension, 34(1):32‚Äì35, January 2016.
[41] Claudio Franceschi, Massimiliano Bonaf√®, Silvana Valensin, Fabiola Olivieri, Maria De Luca, Enzo Ottaviani,
and Giovanna De Benedictis. Inflamm-aging: an evolutionary perspective on immunosenescence. Annals of the
new York Academy of Sciences, 908(1):244‚Äì254, 2000.
[42] Irene Maeve Rea, David S. Gibson, Victoria McGilligan, Susan E. McNerlan, H. Denis Alexander, and Owen A.
Ross. Age and age-related diseases: Role of inflammation triggers and cytokines. Frontiers in Immunology, 9,
April 2018.
[43] Sungha Park and Edward G. Lakatta. Role of inflammation in the pathogenesis of arterial stiffness. Yonsei Medical
Journal, 53(2):258, 2012.
[44] K. M. Madden, C. Lockhart, D. Cuff, T. F. Potter, and G. S. Meneilly. Short-term aerobic exercise reduces
arterial stiffness in older adults with type 2 diabetes, hypertension, and hypercholesterolemia. Diabetes Care,
32(8):1531‚Äì1535, June 2009.
[45] John H Fountain and Sarah L Lappin. Physiology, renin angiotensin system. In StatPearls [Internet]. StatPearls
Publishing, 2019.
[46] Keiji Kuba, Yumiko Imai, Takayo Ohto-Nakanishi, and Josef M Penninger. Trilogy of ace2: A peptidase in the
renin‚Äìangiotensin system, a sars receptor, and a partner for amino acid transporters. Pharmacology & therapeutics,
128(1):119‚Äì128, 2010.
[47] Mariela M Gironacci, Hugo P Adamo, Gerardo Corradi, Robson A Santos, Pablo Ortiz, and Oscar A Carretero.
Angiotensin (1-7) induces mas receptor internalization. Hypertension, 58(2):176‚Äì181, 2011.
[48] Luis C Matavelli and Helmy M Siragy. At2 receptor activities and pathophysiological implications. Journal of
cardiovascular pharmacology, 65(3):226, 2015.
[49] S√©bastien Foulquier, U Muscha Steckelings, and Thomas Unger. Impact of the at 2 receptor agonist c21 on blood
pressure and beyond. Current hypertension reports, 14(5):403‚Äì409, 2012.
[50] Elena Kaschina, Aleksandra Grzesiak, Jun Li, Anna Foryst-Ludwig, Melanie Timm, Franziska Rompe, Manuela
Sommerfeld, U Rudolf Kemnitz, Caterina Curato, Pawel Namsolleck, et al. Angiotensin ii type 2 receptor
stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?
Circulation, 118(24):2523‚Äì2532, 2008.
[51] Paolo Gelosa, Alice Pignieri, Lars F√§ndriks, Marc De Gasparo, Anders Hallberg, Cristina Banfi, Laura Castiglioni,
Lucia Turolo, Uliano Guerrini, Elena Tremoli, et al. Stimulation of at2 receptor exerts beneficial effects in
stroke-prone rats: focus on renal damage. Journal of hypertension, 27(12):2444‚Äì2451, 2009.
[52] Luis C Matavelli, Jiqian Huang, and Helmy M Siragy. Angiotensin at2 receptor stimulation inhibits early renal
inflammation in renovascular hypertension. Hypertension, 57(2):308‚Äì313, 2011.
[53] Mohammad Amin Zaman, Suzanne Oparil, and David A Calhoun. Drugs targeting the renin‚Äìangiotensin‚Äì
aldosterone system. Nature reviews Drug discovery, 1(8):621‚Äì636, 2002.
[54] Andrew M South, Laurie Tomlinson, Daniel Edmonston, Swapnil Hiremath, and Matthew A Sparks. Controversies
of renin‚Äìangiotensin system inhibition during the covid-19 pandemic. Nature Reviews Nephrology, pages 1‚Äì3,
2020.
[55] Ashlee N Ford Versypt, Grace K Harrell, and Alexandra N McPeak. A pharmacokinetic/pharmacodynamic model
of ace inhibition of the renin-angiotensin system for normal and impaired renal function. Computers & Chemical
Engineering, 104:311‚Äì322, 2017.
17

A PREPRINT - J ULY 21, 2020

[56] James P Byers and Jeffrey G Sarver. Pharmacokinetic modeling. In Pharmacology, pages 201‚Äì277. Elsevier,
2009.
[57] Minu R Pilvankar, Michele A Higgins, and Ashlee N Ford Versypt. Mathematical model for glucose dependence
of the local renin‚Äìangiotensin system in podocytes. Bulletin of mathematical biology, 80(4):880‚Äì905, 2018.
[58] Arthur Lo, Jennifer Beh, Hector De Leon, Melissa K Hallow, Ramprasad Ramakrishna, Manoj Rodrigo, Anamika
Sarkar, Ramesh Sarangapani, and Anna Georgieva. Using a systems biology approach to explore hypotheses
underlying clinical diversity of the renin angiotensin system and the response to antihypertensive therapies. In
Clinical Trial Simulations, pages 457‚Äì482. Springer, 2011.
[59] S. Sharif, F. L. J. Visseren, W. Spiering, P. A. Jong, M. L. Bots, and J. Westerink and. Arterial stiffness as a
risk factor for cardiovascular events and all-cause mortality in people with type 2 diabetes. Diabetic Medicine,
36(9):1125‚Äì1132, April 2019.
[60] Rafael de Oliveira Alvim, Paulo Caleb Junior Lima Santos, Mariane Musso, Roberto de S√° Cunha, Jos√© Krieger,
Jos√© Mill, and Alexandre Pereira. Impact of diabetes mellitus on arterial stiffness in a representative sample of an
urban brazilian population. Diabetology & Metabolic Syndrome, 5(1):45, 2013.
[61] Yao Lu, Raimund Pechlaner, Jingjing Cai, Hong Yuan, Zhijun Huang, Guoping Yang, Jiangang Wang, Zhiheng
Chen, Stefan Kiechl, and Qingbo Xu. Trajectories of age-related arterial stiffness in chinese men and women.
Journal of the American College of Cardiology, 75(8):870‚Äì880, March 2020.
[62] Alejandro Diaz, Mat√≠as Tringler, Sandra Wray, Agust√≠n J. Ramirez, and Edmundo I. Cabrera Fischer. The effects
of age on pulse wave velocity in untreated hypertension. The Journal of Clinical Hypertension, 20(2):258‚Äì265,
December 2017.
[63] K. Kodama, M. Horikoshi, K. Toda, S. Yamada, K. Hara, J. Irie, M. Sirota, A. A. Morgan, R. Chen, H. Ohtsu,
S. Maeda, T. Kadowaki, and A. J. Butte. Expression-based genome-wide association study links the receptor CD44
in adipose tissue with type 2 diabetes. Proceedings of the National Academy of Sciences, 109(18):7049‚Äì7054,
April 2012.
[64] Sviatlana V. Zhyzhneuskaya, Ahmad AL-Mrabeh, Alison C. Barnes, Benjamin Aribisala, Kieren G. Hollingsworth,
Helen Pilkington, Naveed Sattar, Michael E. Lean, and Roy Taylor. 66-OR: Remission of type 2 diabetes for two
years is associated with full recovery of beta-cell functional mass in the diabetes remission clinical trial (DiRECT).
Diabetes, 68(Supplement 1):66‚ÄìOR, June 2019.
[65] Michael EJ Lean, Wilma S Leslie, Alison C Barnes, Naomi Brosnahan, George Thom, Louise McCombie,
Carl Peters, Sviatlana Zhyzhneuskaya, Ahmad Al-Mrabeh, Kieren G Hollingsworth, Angela M Rodrigues,
Lucia Rehackova, Ashley J Adamson, Falko F Sniehotta, John C Mathers, Hazel M Ross, Yvonne McIlvenna,
Renae Stefanetti, Michael Trenell, Paul Welsh, Sharon Kean, Ian Ford, Alex McConnachie, Naveed Sattar, and
Roy Taylor. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label,
cluster-randomised trial. The Lancet, 391(10120):541‚Äì551, February 2018.
[66] G√∂khan S. Hotamisligil. Inflammation and metabolic disorders. Nature, 444(7121):860‚Äì867, December 2006.
[67] Matthias B Schulze, Kurt Hoffmann, JoAnn E Manson, Walter C Willett, James B Meigs, Cornelia Weikert,
Christin Heidemann, Graham A Colditz, and Frank B Hu. Dietary pattern, inflammation, and incidence of type 2
diabetes in women. The American Journal of Clinical Nutrition, 82(3):675‚Äì684, September 2005.
[68] DH Solomon, TJ Love, C Canning, and et al. Risk of diabetes among patients with rheumatoid arthritis, psoriatic
arthritis and psoriasis. Ann Rheum Dis., 69(12):2114‚Äì2117, 2010.
[69] CC Su, IeC Chen, FN Young, and et al. Risk of diabetes in patients with rheumatoid arthritis: a 12-year
retrospective cohort study. J Rheumatol., 40(9):1513‚Äì1518, 2013.
[70] MC Lu, ST Yan, WY Yin, and et al. Risk of rheumatoid arthritis in patients with type 2 diabetes: a nationwide
population-based case-control study. PLoS One, 9(7):e101528, 2014.
[71] Vincent C Rideout. Mathematical and computer modeling of physiological systems. Prentice Hall Englewood
Cliffs, NJ:, 1991.
[72] Thomas Heldt, Eun B Shim, Roger D Kamm, and Roger G Mark. Computational modeling of cardiovascular
response to orthostatic stress. Journal of applied physiology, 92(3):1239‚Äì1254, 2002.
[73] K Lu, JW Clark Jr, FH Ghorbel, DL Ware, and A Bidani. A human cardiopulmonary system model applied
to the analysis of the valsalva maneuver. American Journal of Physiology-Heart and Circulatory Physiology,
281(6):H2661‚ÄìH2679, 2001.
[74] Daniel Zinemanas, Rafael Beyar, and Samuel Sideman. Relating mechanics, blood flow and mass transport in the
cardiac muscle. International journal of heat and mass transfer, 37:191‚Äì205, 1994.
18

A PREPRINT - J ULY 21, 2020

[75] M Di Rienzo et al. Circulatory model of baro-and cardio-pulmonary reflexes. Blood Pressure and Heart Rate
Variability: Computer Analysis, Modelling and Clinical Applications, 4:56, 1993.
[76] Thomas S Lisse and Martin Hewison. Vitamin d: a new player in the world of mtor signaling, 2011.
[77] Stefan Pilz, Andreas Tomaschitz, Eberhard Ritz, and Thomas R Pieber. Vitamin d status and arterial hypertension:
a systematic review. Nature Reviews Cardiology, 6(10):621, 2009.
[78] Merav Cohen-Lahav, Shraga Shany, David Tobvin, Cidio Chaimovitz, and Amos Douvdevani. Vitamin d decreases
nfŒ∫b activity by increasing iŒ∫bŒ± levels. Nephrology Dialysis Transplantation, 21(4):889‚Äì897, 2006.
[79] William B Grant, Henry Lahore, Sharon L McDonnell, Carole A Baggerly, Christine B French, Jennifer L Aliano,
and Harjit P Bhattoa. Evidence that vitamin d supplementation could reduce risk of influenza and covid-19
infections and deaths. Nutrients, 12(4):988, 2020.
[80] Raghu V Durvasula and Stuart J Shankland. Activation of a local renin angiotensin system in podocytes by
glucose. American Journal of Physiology-Renal Physiology, 294(4):F830‚ÄìF839, 2008.
[81] Benito Yard, Yuxi Feng, Hanno Keller, Christa Mall, and Fokko van der Woude. Influence of high glucose
concentrations on the expression of glycosaminoglycans and n-deacetylase/n-sulphotransferase mrna in cultured
skin fibroblasts from diabetic patients with or without nephropathy. Nephrology Dialysis Transplantation,
17(3):386‚Äì391, 2002.
[82] Falguni Das, Nandini Ghosh-Choudhury, Nirmalya Dey, Amit Bera, Meenalakshmi M Mariappan, Balakuntalam S
Kasinath, and Goutam Ghosh Choudhury. High glucose forces a positive feedback loop connecting akt kinase and
foxo1 transcription factor to activate mtorc1 kinase for mesangial cell hypertrophy and matrix protein expression.
Journal of Biological Chemistry, 289(47):32703‚Äì32716, 2014.
[83] Richard C. Becker. COVID-19 update: Covid-19-associated coagulopathy. Journal of Thrombosis and Thrombolysis, May 2020.
[84] Marco Viceconti, Gordon Clapworthy, Debora Testi, Fulvia Taddei, and Nigel McFarlane. Multimodal fusion of
biomedical data at different temporal and dimensional scales. Computer Methods and Programs in Biomedicine,
102(3):227‚Äì237, June 2011.
[85] W ELLIOTT. Circadian variation in blood pressureImplications for the elderly patient. American Journal of
Hypertension, 12(2):43S‚Äì49S, February 1999.
[86] Lewis A. Lipsitz. Loss of ‚Äôcomplexity‚Äô and aging. JAMA, 267(13):1806, April 1992.
[87] Leon Glass, Michael C. Mackey, and Paul F. Zweifel. From clocks to chaos: The rhythms of life. Physics Today,
42(7):72‚Äì72, July 1989.
[88] John P. Hirdes, Dinnus H. Frijters, and Gary F. Teare. The MDS-CHESS scale: A new measure to predict mortality
in institutionalized older people. Journal of the American Geriatrics Society, 51(1):96‚Äì100, January 2003.
[89] A E Ades, Nicky J Welton, Deborah Caldwell, Malcolm Price, Aicha Goubar, and Guobing Lu. Multiparameter
evidence synthesis in epidemiology and medical decision-making. Journal of Health Services Research & Policy,
13(3_suppl):12‚Äì22, October 2008.
[90] Rudolf N. Cardinal. Clinical records anonymisation and text extraction (CRATE): an open-source software system.
BMC Medical Informatics and Decision Making, 17(1), April 2017.
[91] Tamara T. M√ºller and Pietro Lio. PECLIDES neuro: A personalisable clinical decision support system for
neurological diseases. Frontiers in Artificial Intelligence, 3, April 2020.
[92] Hiroshi Shionoiri, Shin-ichiro Ueda, Kohsuke Minamisawa, Mayumi Minamisawa, Izumi Takasaki, Koichi
Sugimoto, Eiji Gotoh, and Masao Ishii. Pharmacokinetics and pharmacodynamics of benazepril in hypertensive
patients with normal and impaired renal function. Journal of cardiovascular pharmacology, 20(3):348‚Äì357, 1992.
[93] Shinji Hisatake, Shunsuke Kiuchi, Takayuki Kabuki, Takashi Oka, Shintaro Dobashi, and Takanori Ikeda. Serum
angiotensin-converting enzyme 2 concentration and angiotensin-(1‚Äì7) concentration in patients with acute heart
failure patients requiring emergency hospitalization. Heart and vessels, 32(3):303‚Äì308, 2017.
[94] Gianna Toffolo, Richard N Bergman, Diane T Finegood, Charles R Bowden, and Claudio Cobelli. Quantitative
estimation of beta cell sensitivity to glucose in the intact organism: a minimal model of insulin kinetics in the dog.
Diabetes, 29(12):979‚Äì990, 1980.
[95] Willy Malaisse, FRANCINE MALAISSE-LAGAE, and PETER H WRIGHT. A new method for the measurement
in vitro of pancreatic insulin secretion. Endocrinology, 80(1):99‚Äì108, 1967.
19

A PREPRINT - J ULY 21, 2020

[96] Richard N Bergman, Lawrence S Phillips, and Claudio Cobelli. Physiologic evaluation of factors controlling
glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to
intravenous glucose. The Journal of clinical investigation, 68(6):1456‚Äì1467, 1981.
[97] Diane T Finegood. Application of the minimal model of glucose kinetics. The Minimal Model Approach and
Determinants of Glucose Tolerance, 7:51‚Äì122, 1997.
[98] Toshinori Imamura, Michael Koffler, J Harold Helderman, Dale Prince, Richard Thirlby, Lindsey Inman, and
Roger H Unger. Severe diabetes induced in subtotally depancreatized dogs by sustained hyperglycemia. Diabetes,
37(5):600‚Äì609, 1988.

20

A PREPRINT - J ULY 21, 2020

A
A.1

Appendix
Website

Figure 7: Website dashboard for computational patients.

21

A PREPRINT - J ULY 21, 2020

A.2

Equations of the renin-angiotensin system
100[DRU G]m
m
[DRU G]m
50 + [DRU G]

I=

production rate

d[AGT ]
dt

z }| {
kAGT

=

(16)

renin-catalyzed conversion to ANG I

degradation

}|
{
}|
{ z

ln(2)
‚àí aRenin G + bRenin [AGT ] ‚àí
[AGT ]
hAGT
z


(17)

production rate

d[Renin]
dt

z
=

}|

ln 2

hRenin

{

[Renin]0
ANG II inhibition feedback

+

z
}|
!{

kf,sys [AN GII]0,sys 
[AN GII]0,sys
[AN GII]0 ‚àí [AN GII] 1 ‚àí ([AN GII]0 ‚àí [AN GII])
[AN GII]0
fsys [AN GII]0
degradation

z
‚àí

ln 2

}|

hRenin

{

[Renin]

(18)

renin-catalyzed conversion of AGT

d[AN GI]
dt

=

z

ANG II feedback on renin

}|
{ z
}|


{
aRenin G + bRenin [AGT ] + kRenin [Renin] ‚àí [Renin]0

ACE-catalyzed conversion to ANG II subject to inhibition

z

‚àí

}|




aACE G + bACE [AN GI] 1 ‚àí I

{

conversion to ANG-(1-7) and ANG-(1-9)

z

}|

‚àí kN EP + kACE2



{
[AN GI] ‚àí

degradation

z
‚àí

ln2

}|

hAN GI

{

[AN GI]

(19)

ACE-catalyzed conversion to ANG II subject to inhibition

d[AN GII]
dt

z


=

}|


aACE G + bACE


{
[AN GI] 1 ‚àí I

conversion to AT1R, AT2R, APA, and ANG-(1-7)

‚àí

z

}|
{


kACE2 + aAT 1 G + bAT 1 + kAT 2 + kAP A [AN GII]


degradation

z
‚àí
A.3
A.3.1

ln2

}|

hAN GII

{

[AN GII]

(20)

Equations of the open-loop circulatory model
Four-chambered heart
Ô£±
1
Ô£¥
Ô£¥HRa =
Ô£¥
Ô£¥
HP/60
Ô£¥
Ô£¥
s
Ô£¥
Ô£¥
Ô£≤
T s2
t ‚â• tHB (n + 1) ‚àí P Rint ‚àí of f v =‚áí Tsa = T s1a
HR
Ô£¥
a /60
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
tP wave = tHB ‚àí P Rint ‚àí of f v
Ô£¥
Ô£¥
Ô£≥
n=n+1
22

(21)

A PREPRINT - J ULY 21, 2020

Ô£±
1
Ô£¥
Ô£¥
HRv =
Ô£¥
Ô£¥
HP/60
Ô£¥
Ô£¥
s
Ô£¥
Ô£¥
Ô£¥
Ô£¥
T s2
Ô£¥
Ô£¥
Tsv = T s1v
Ô£¥
Ô£¥
Ô£¥
HR
v /60
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£≤tRwave = tHB ‚àí of f v
t ‚â• tHB (m+1)‚àíof f v =‚áí m = n
Ô£¥
Ô£¥
Ô£±
Ô£¥
Ô£¥
Vi,vd0
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£≤
Ô£¥
Vi,vs0
Ô£¥
Ô£¥
Ô£¥
Vvar,i,vs0 =
Ô£¥
Ô£¥
Ô£¥
Vi,v ‚àí Vi,vd0
Ô£¥
Ô£¥
Ô£¥
Ô£≥Vi,vs0 ‚àí Vi,vd0
+ Vi,vd0
Ô£¥
Ô£¥
Ô£¥
EDVi,v ‚àí Vi,vd0
Ô£¥
Ô£¥
Ô£≥
afcon2 = afcon

Vi,v < Vi,vd0
Vi,v > EDViv
Vi,vd0 ‚â§ Vi,v ‚â§ EDViv
(22)

HR = HRv

(23)

Emax,i,v = Ke,i,v Emax,i,v1

(24)

ta,REL = t ‚àí tP wave

(25)

tv,REL = t ‚àí tRwave

(26)

Ô£±
ti,REL
Ô£¥
1 ‚àí cos œÄ
Ô£¥
Ô£¥
Ô£¥
Ts,i
Ô£¥
Ô£¥
Ô£¥
Ô£¥
2
Ô£≤
ti,REL ‚àí Ts,i
yi =
1 + cos 2œÄ
Ô£¥
Ô£¥
Ts,i
Ô£¥
Ô£¥
Ô£¥
Ô£¥
Ô£¥
2
Ô£¥
Ô£≥
0

0 ‚â§ ti,REL < Ts,i
(27)
Ts,i ‚â§ ti,REL < 1.5Ts,i
ti,REL ‚â• 1.5Ts,i

Ei,j = yj (Emax,i,j ‚àí Emin,i,j ) + Emin,i,j

(28)

Vi,a,0 = (1 ‚àí ya )(Vi,a,d0 ‚àí Vi,a,s0 ) + Vi,a,s0

(29)

Vi,v,0 = (1 ‚àí yv )(Vi,v,d0 ‚àí Vvar,i,vs0 ) + Vvar,i,vs0

(30)

œà(v) = Kxp

1
ev/Kxv

‚àí1

(31)

Pi,a = Ei,a (Vi,a ‚àí Vi,a0 ) ‚àí œà(Vi,a )

(32)

Pi,v = Ei,v (Vi,v ‚àí Vi,v0 )afcon2 ‚àí œà(Vi,v )

(33)

Fi,a

Ô£±
Ô£≤ Pi,a ‚àí Pi,v
Ri,a
=
Ô£≥
0
23

Pi,a > Pi,v
Pi,a ‚â§ Pi,v

(34)

A PREPRINT - J ULY 21, 2020

Fr,v

Fl,v

Ô£±
Ô£≤ Pr,v ‚àí Ppap
Rr,v
=
Ô£≥
0

Pr,v > Ppap

Ô£±
Ô£≤ Pl,v ‚àí Paop
Rl,v
=
Ô£≥
0

Pl,v > Paop

(36)

Pl,v ‚â§ Paop

dVr,a
dt

A.3.2

(35)

Pr,v ‚â§ Ppap

=

(37)

dVr,a
Fvc + Fcorvn
=
dt
Fr,a

(38)

Fr,a
dVr,v
=
dt
Frv

(39)

dVl,a
Fpv
=
dt
Fl,a

(40)

Fl,a
dVl,v
=
dt
Fl,v

(41)

Systemic circulation
Pvc =

(
K1 (Vvc ‚àí Vvc0 ) ‚àí œà(Vvc )
D2 + K2 e

Vvc /Vmin,vc

‚àí œà(Vvc )

Vvc > Vvc0
Vvc ‚â§ Vvc0

COmod = Frv,sm
SV =

"
Rcrb
M APmod =

COmod
HR

(42)
(43)

(44)

ABPshif t = ABPmeas (t ‚àí of f v)

(45)

Kv = Kv1 Ksv

(46)

#
Vaod ‚àí Vaod0
Rtaod AOFmod ‚àí Rtaod Faod +
‚àí œà(Vaod ) + Pvc Rtaod
Caod
Rcrb + Rtaod
Paod = ABPshif t
Vsap ‚àí Vsap0
‚àí œà(Vsap )
Csap
"
#
Vsa ‚àí Vsa0
= Kc log10
+1
Do

Psap =

Psa,a

Psa,p = Kp1 eœÑp (Vsa ‚àíVsa0 ) + Kp2 (Vsa ‚àí Vsa0 )2
24

(47)
(48)

(49)

(50)
(51)

A PREPRINT - J ULY 21, 2020

Psa = fvaso Psa,a + (1 ‚àí fvaso )Psa,p

Psc =

Vsc ‚àí V sc0
‚àí œà(Vsc )
Csc
"

Psv = ‚àíKv log10

Rsa = Kr e4fvaso

Rvc = KR

Vmax,sv
‚àí 0.99
Vsv

2
Vsa,max
+
2
Vsa

(52)

(53)
#
(54)

!
+ Rsa0

2
Vmax,vc
+ R0
2
Vvc

(55)

(56)

M APmod ‚àí Pvc
Rcrb

(57)

Fsap =

Psap ‚àí Psa
Rsap

(58)

Fsa =

Psa ‚àí Psc
Rsa

(59)

Fsc =

Psc ‚àí Psv
Rsc

(60)

Fsv =

Psv ‚àí Pvc
Rsv

(61)

Fvc =

Pvc ‚àí Pra
Rvc

(62)

Fcrb =

dVaop
=
dt

Paop ‚àí

Vaop ‚àí Vaop0
Caop
Rtaop

(63)

dVaod
= AOFmod ‚àí Faod ‚àí Fcrb
dt

(64)

dVsa
= Fsap ‚àí Fsa
dt

(65)

dVsap
= Faod ‚àí Fsap
dt

(66)

dVsc
= Fsa ‚àí Fsc
dt

(67)

dVsv
= Fsc ‚àí Fsv
dt

(68)

dVvc
= Fsv + Fcrb ‚àí Fvc
dt

(69)

25

A PREPRINT - J ULY 21, 2020

dAOFmod
Kcomap
= (M APmeas ‚àí M APmod )
dt
60

(70)

dFrv,sm
Frv ‚àí Frv,sm
=
dt
œÑco

(71)

M APmod ‚àí Faod Raod ‚àí Psap
dFaod
=
dt
Laod

(72)

Flv ‚àí
dPpaop
=
dt

dVaop
‚àí Faop ‚àí Fcorepi
dt
Ccorepi

(73)

dM APmeas
ABPshif t ‚àí M APmeas
=
dt
œÑM AP

(74)

P AFmeas ‚àí COmea
dCOmea
=
dt
œÑco

(75)

ABPshif t ‚àí ABPf ol
dABPf ol
=
dt
œÑABP

(76)

A.3.3

Pulmonary circulation
Ô£±
!
Ô£¥
Vpap ‚àí Vpap0
Ô£¥
Ô£¥
Rtpap Prv ‚àí Rrv Fpap Rtpap + Rrv
‚àí œà(Vpap )
Ô£¥
Ô£¥
Ô£¥
Cpap
Ô£¥
Ô£¥
Ô£¥
Ô£≤Ppap1 =
Rtpap + Rrv
Ppap =
!
Ô£¥
Ô£¥
Vpap ‚àí Vpap0
Ô£¥
Ô£¥
‚àí œà(Vpap )
‚àíRrv Fpap Rtpap + Rrv
Ô£¥
Ô£¥
Ô£¥
Cpap
Ô£¥
Ô£¥
Ô£≥Ppap2 =
Rrv
Ppad = Fpap Rtpad ‚àí Fpad Rtpad +

Vpad ‚àí Vpad0
‚àí œà(Vpad )
Cpad

Prv > Ppap1
(77)
Prv ‚â§ Ppap1
(78)

Vp,i ‚àí Vp,i,0
‚àí œà(Vp,i )
Cp,i

(79)

Fps =

Ppa ‚àí Ppv
Rps

(80)

Fpa =

Ppa ‚àí Ppc
Rpa

(81)

Fpc =

Ppc ‚àí Ppv
Rpc

(82)

Fpv =

Ppv ‚àí Ppa
Rpv

(83)

Vp,i =

dFpap
Ppap ‚àí Ppad ‚àí Fpap Rpap
=
dt
Lpap

(84)

dFpad
Ppad ‚àí Ppa ‚àí Fpad Rpad
=
dt
Lpad

(85)

26

A PREPRINT - J ULY 21, 2020

A.3.4

dVpad
= Fpap ‚àí Fpad
dt

(86)

dVpap
= Frv ‚àí Fpap
dt

(87)

dVpa
= Fpad ‚àí Fps ‚àí Fpa
dt

(88)

dVpc
= Fpa ‚àí Fpc
dt

(89)

dVpv
= Fpc + Fps ‚àí Fpv
dt

(90)

Pcorepi = Paop

(91)

Coronary circulation

Vcorintra ‚àí Vcorintra0
‚àí œà(V)
Ccorintra

(92)

Vcorcap ‚àí Vcorcap0
‚àí œà(Vcorcap )
Ccorcap

(93)

Vcorvn ‚àí Vcorvn0
‚àí œà(Vcorvn )
Ccorvn

(94)

Pcorintra =

Pcorcap =

Pcorvn =

$
Pim =

Plv
2

%
(95)

Pcorintrac = Pcorintra + Pim

(96)

Pcorcapc = Pcorcap + Pim

(97)

Pcorvnc = Pcorvn

(98)

Fcorepi =

Fcorintra =

Fcorcap =

Pcorepi ‚àí Pcorintrac
Rcorepi

(99)

Pcorintrac ‚àí Pcorcapc
Rcorintra

(100)

Pcorcapc ‚àí Pcorvnc
Rcorcap

(101)

Pcorvnc ‚àí Pra
Rcorvn

(102)

Fcorvn =

dVcorepi
dVvaop
= Flv ‚àí
‚àí Faop ‚àí Fcorepi
dt
dt
27

(103)

A PREPRINT - J ULY 21, 2020

A.3.5

dVcorintra
= Fcorepi ‚àí Fcorintra
dt

(104)

dVcorcap
= Fcorintra ‚àí Fcorcap
dt

(105)

dVcorvn
= Fcorcap ‚àí Fcorvn
dt

(106)

bvaso = 1 ‚àí avaso

(107)

Baroreceptor

fvaso = avaso +

bvaso
eœÑvaso (Nvaso ‚àíNo,vaso )) + 1

Nbr,t =

dNbr,t
=
dt

dNbr
dt

(109)

dABPf ol
‚àí(a2 + a)Nbr,t ‚àí Nbr + K ABPshif t + a1
dt

!
(110)

a2 a

Ô£±
Ô£≤ ‚àíNi + Ki Nbr (t ‚àí li )
dNi
Ti
=
Ô£≥
dt
0
A.3.6

(108)

t ‚àí tHB (0) > li

(111)

t ‚àí tHB (0) ‚â§ li

Blood volumes
Vcorcic = Vcorepi + Vcorintra + Vcorcap + Vcorvn

(112)

Vheart = Vra + Vrv + Vla + Vlv + Vcorcic

(113)

Vsysart = Vaop + Vaod + Vsap + Vsa

(114)

Vsysven = Vsv + Vvc

(115)

Vpulart = Vpap + Vpad + Vpa

(116)

T BV = Vheart + Vsysart + Vsc + Vsysven + Vpulart + Vpc + Vpv

(117)

28

A.4 Parameters of the renin-angiotensin system
Table 3: Pharmacokinetic parameters
Parameter
ka
ke
V /F

NRF

IRF

1.907
1.33 √ó 10
7.09 √ó 10

Description

h

[55, 92]

absorption rate constant

‚àí2

h

‚àí1

[55, 92]

elimination rate constant

5

mL

[55, 92]

ratio of the volume of distribution to the fraction of the drug absorbed

3.45 √ó 10

4

Sources

‚àí1

1.645
‚àí1

Units

1.07 √ó 10

Table 4: Pharmacodynamic parameters
Parameter
kAGT
kRenin

Value
2.27 √ó 10

6

6.44 √ó 10

4

Units

Sources

Description

nmol/L/h

[57, 14]

constant production rate of AGT

‚àí1

[55, 14]

ANG-I production rate due to renin

‚àí1

h

29

kN EP

0.583

h

[57, 14]

NEP-catalyzed conversion rate from ANG-I to ANG-(1-7)

kAT 2

25.1

h‚àí1

[57, 14]

rate parameter for binding of ANG II to AT1R

kAP A

43.6

h‚àí1

[57, 14]

APA-catalyzed conversion rate from ANG-II to ANG-III

hAGT

10.0

h

[58, 57, 14]

AGT half-life degradation rate

hRenin

0.250

h

[57, 14]

renin half-life degradation rate

h

[58, 57, 14]

ANG-I half-life degradation rate

hAN GI

1.72 √ó 10

‚àí4

‚àí3

5 √ó 10

h

[58, 57, 14]

ANG-II half-life degradation rate

[Drug]50

2.20

ng/mL

[92, 57, 14]

drug concentration yielding 50% inhibition

m

0.99

-

[92, 57, 14]

degree of sigmoidicity of the Hill function

[57, 14]

slope of the linear dependence of renin from glucose

h

[57, 14]

intercept of the linear dependence of renin from glucose

5.47 √ó 10

‚àí4

bRenin

6.16 √ó 10

‚àí11

aACE

0.889

L/mmol/h

[57, 14]

slope of the linear dependence of ACE from glucose

bACE

163

h‚àí1

[57, 14]

intercept of the linear dependence of ACE from glucose

aAT 1

2.55

L/mmol/h

aRenin

bAT 1
kf,sys

464
6.25 √ó 10

L/mmol/h
‚àí1

[57, 14]

slope of the linear dependence of AT1R from glucose

‚àí1

[57, 14]

intercept of the linear dependence of AT1R from glucose

‚àí1

[55, 14]

ANG-II feedback parameter on renin

h
‚àí2

h

A PREPRINT - J ULY 21, 2020

hAN GII

Table 4 continued from previous page
Parameter

Value

fsys

0.397

Units

Sources

Description

nmol/L

[55, 14]

ANG-II feedback parameter on renin

1.70 √ó 10

7

nmol/L

[57, 14]

AGT initial concentration

[Renin]0

2.06 √ó 10

‚àí4

nmol/L

[55, 14]

renin initial concentration

[AN GI]0

271

nmol/L

[57, 14]

ANG-I initial concentration

[AN GII]0

21.0

[AGT ]0

nmol/L

[57, 14]

ANG-II initial concentration

1.65 √ó 10

‚àí2

nmol/L

[55, 14]

systemic ANG-II initial concentration for normal renal individuals

[AN GII]0,sysIRF

2.05 √ó 10

‚àí2

nmol/L

[55, 14]

systemic ANG-II initial concentration for impaired renal individuals

hAN G17

0.5

h

[58]

ANG-17 half-life degradation rate

[AN G17]0

9.858

nmol/L

[93]

ANG-17 initial concentration

hAT 1R

0.2

h

[58]

AT1R half-life degradation rate

[AT 1R]0

16.2

nmol/L

[93]

AT1R initial concentration

hAT 2R

0.2

h

[58]

AT2R half-life degradation rate

[AT 2R]0

5.4

nmol/L

[93]

AT2R initial concentration

[57, 14]

ACE-catalyzed conversion rate from ANG-II to ANG-(1-7)

-

severity of SARS-CoV-2 infection

-

efficiency of anti-inflammatory pathways

[AN GII]0,sysNRF

30

kACE2,0

‚àí1

0.385

h

‚àí1

sI

0.1

h

eAI

0.347

-

L/nmol

A.5 Parameters of the diabetic model

Parameter
k
Œ±
œÉ
R0
R1

Value
432
20000
43.2
864
1

Units
‚àí1

d

2

mg dl

‚àí2

¬µU ml

d

Description

[94]

combined insulin uptake at the liver, kidneys, and insulin receptors

[95]

glucose concentration yielding 50% of insulin secretion

[96, 95, 94]

maximal rate secretion of insulin by Œ≤ cells

‚àí1 ‚àí1

[96, 97]

net rate of production at zero glucose

‚àí1

-

net rate of glucose increase due to meals

mg dl
ml dl

‚àí1 ‚àí1

Sources

d

g

‚àí1

A PREPRINT - J ULY 21, 2020

Table 5: Diabetic parameters

Table 5 continued from previous page
Parameter

Value

Units

Sources

Description

R2

0.1

ml dl‚àí1 kcal‚àí1

-

net rate of glucose consumption due to workouts

EG0
SI (normal)
SI (diabetic)
r0
r1

0.44

d

1.62
0.52

‚àí1

[96, 97]

total glucose effectiveness at zero insulin

ml ¬µU

‚àí1 ‚àí1

d

[97]

normal insulin sensitivity

ml ¬µU

‚àí1 ‚àí1

[97]

diabetic insulin sensitivity

d

‚àí1

0.06

d

0.00084

mg

‚àí1
‚àí2

[96, 98, 97]

death rate at zero glucose

‚àí1

[96, 98, 97]

I-order coefficient for Œ≤ cell replication

‚àí1

[96, 98, 97]

II-order coefficient for Œ≤ cell replication

dl d

31

r2

0.0000024

mg

dl d

i0

87

-

[13]

insulin resistance self-inhibition rate

m

2

-

[13]

insulin resistance progression rate due to pro-inflammatory cytokines

q

0.017

ml/¬µU

[13]

insulin resistance progression rate due to insulin concentration

I0

13.59

¬µU/ml

[13]

initial insulin concentration

G0

100

ml/dl

[13]

initial glucose concentration

Œ≤f,0

407.73

-

[13]

number of functional Œ≤-cells

IR,0

0.359

-

-

initial insulin resistance

A.6 Parameters of the stiffness model
Table 6: Stiffness parameters
Value

Units

Sources

kSARS

0.15

h

inflammation rate due to SARS-CoV-2

kD

0.001

mL/ng

inflammation rate due to ACEi surplus

kG

0.1

L/mmol

inflammation rate due to glucose surplus

kef f (healthy state)

0.035

-

anti-inflammatory response rate

kef f (during infection)

0.693

-

anti-inflammatory response rate

Œ≤1

0.006

-

compliance reduction rate due to ageing

Œ≤0

1.2

-

compliance reduction intercept due to ageing

Description

A PREPRINT - J ULY 21, 2020

Parameter

Table 6 continued from previous page
Parameter

Value

Units

IR0

0.385

-

Œ≤h

0.0008

Œ≤D

0.05

[heparin]0

inflammatory response initial condition

mmHg mL U

‚àí1

mmHg mL ng

5000

[D]0

Description

U ml

‚àí1

heparin impact on blood pressure
vitamin D impact on blood pressure
initial heparin dose for intra venous continuous infusion treatment

‚àí1

30

‚àí1

ng mL

vitamin D recommended concentration

A.7 Parameters of the open-loop circulatory model

32

Value

Units

Description

T s1v

0.349

sec

Scaler to set ventricular systolic fraction of heart cycle

T s1a

0.2

sec

Scaler to set atrial systolic fraction of heart cycle

T s2

1

hz

Unit balance scalar for Tsa and Tsv functions

of f v

0.0263

sec

Parameter to match model and measured end-diastolic ABP

V lvd0

71.816

ml

Unstressed end-diastolic left ventricle volume

V lvs0

23.699

ml

Unstressed end-systolic left ventricle volume

V rvd0

102.881

ml

Unstressed end-diastolic right ventricle volume

V rvs0

53.498

ml

Unstressed end-systolic right ventricle volume

V lad0

70

ml

Unstressed end-diastolic left atrium volume

V las0

40

ml

Unstressed end-systolic left atrium volume

V rad0

60

ml

Unstressed end-diastolic right atrium volume

V ras0

53

ml

Unstressed end-systolic right atrium volume
‚àí1

Rra

0.001

mmHg s ml

Rla

0.001

mmHg s ml‚àí2

Mitral valve resistance

Rlv

0.0001

mmHg s ml‚àí3

Aortic valve resistance

0.0001

‚àí4

Rrv

mmHg s ml

Tricuspid valve resistance

Pulmonary valve resistance

A PREPRINT - J ULY 21, 2020

Parameter

Table 7 continued from previous page

33

Parameter

Value

Units

Description

P Rint

0.12

sec

Difference in atrial, venticular activation times

KElv

1

Scaling factor for maximum left ventricular elastance

KErv

1

Scaling factor for maximum right ventricular elastance

Emaxlv1

5.4

mmHg/ml

Maximum elastance of first left ventricle component

Eminlv

0.09

mmHg/ml

Minimum elastance of first left ventricle component

Emaxrv1

0.53

mmHg/ml

Maximum elastance of first right ventricle component

Eminrv

0.0343

mmHg/ml

Minimum elastance of first right ventricle component

EDV LV

125.993

ml

EDV RV

175.865

ml

Emaxra

0.13

mmHg/ml

Maximum elastance right ventricle

Eminra

0.085

mmHg/ml

Minimum elastance left ventricle

Emaxla

0.299

mmHg/ml

Maximum elastance right ventricle

Eminla

0.185

mmHg/ml

Minimum elastance left ventricle
2

KCOM AP

3

L/mmHg/min

Raop

0.0001

mmHg sec ml‚àí1

Rtaop
Rcrb
Raod

0.02
6.8284
0.0129

Proximal aortic resistance

mmHg sec ml

‚àí1

Transmural proximal aortic resistance

mmHg sec ml

‚àí1

Cerebral circulation resistance

mmHg sec ml

‚àí1

Distal aortic resistance

‚àí1

Transmural distal aortic resistance

1

mmHg sec ml

Rsap

0.003

mmHg sec ml‚àí1

Systemic arteriolar resistance

Rsc

0.155

mmHg sec ml‚àí1

Systemic capillaries resistance

0.138

‚àí1

Rsv
Caop
Caod
Csap
Csc

0.263
0.639
1.482
5.767

mmHg sec ml

Systemic veins resistance

ml mmHg

‚àí1

Aortic proximal compliance

ml mmHg

‚àí1

Aortic distal compliance

ml mmHg

‚àí1

Systemic arterioles compliance

ml mmHg

‚àí1

Systemic capillaries compliance

A PREPRINT - J ULY 21, 2020

Rtaod

Table 7 continued from previous page
Parameter

Value

Units

Description

V aop0

9.520

ml

Proximal aorta unstressed volume

V aod0

23.11

ml

Distal aorta unstressed volume

V sap0

52.94

ml

Systemic arteries unstressed volume

V sc0

71.02

ml

Laop

1e ‚àí 05

Systemic capillaries unstressed volume
2

‚àí1

Proximal aorta intertance

2

‚àí1

Distal aorta inertance

mmHg sec ml

Laod

2e ‚àí 05

mmHg sec ml

Kc

497.785

mmHg

Active vasomotor tone scaling parameter for systemic arterial pressure

Do

50

ml

Active vasomotor tone volume parameter for systemic arterial pressure

V sa0

485.762

ml

Minimal volume of systemic arteries

V sa_max

577.711

ml

Maximal luminal volume of systemic arteries

Kp1

0.0299

mmHg

Kp2

0.05

mmHg ml

Passive vasomotor tone scaling parameter for systemic arterial pressure
‚àí2

Passive vasomotor tone scaling parameter for systemic arterial pressure

34

‚àí1

Kr

0.01

mmHg sec ml

Rsa0

0.581

mmHg sec/ml

Offset parameter for systemic arteriolar resistance

tau_p

0.1

Ksv

0.74

Kv1

30.21

mmHg

Scaling factor for systemic venous pressure

V max_sv

3379.55

ml

Maximal volume of lumped systemic veins

D2

‚àí5

mmHg

Offsetting constant for partially collapsed Vena cava pressure

K1

0.046

mmHg ml‚àí1

Scaling factor for Vena cava PV relationship

K2

0.374

mmHg

0.001

Passive vasomotor tone constant for systemic arterial pressure
Scaling factor used to optimize systemic venous pressure-volume relationship

Scaling factor for partially collapsed Vena cava pressure

mmHg sec ml

‚àí1

Scaling factor for Vena cava resistance

‚àí1

Vena cava resistance offset parameter

R0

0.025

mmHg sec ml

V vc0

129.649

ml

Unstressed volume of Vena cava

V max_vc

350.53

ml

Maximum volume of Vena cava

V min_vc

50.01

ml

Minimum volume of Vena cava

A PREPRINT - J ULY 21, 2020

KR

ml

‚àí1

Pressure scaling constant for systemic arterial resistance

Table 7 continued from previous page
Parameter

Value

Units

Description

tauCO

15

sec

Cardiac output equation time constant

Kxp

2

mmHg

P-V curve shaping parameter

Kxv

8

ml

P-V curve shaping parameter

Kxv1

1

ml

P-V curve shaping parameter

Kxp1

1

mmHg

P-V curve shaping parameter

tauM AP

2

sec

Time constant for mean arterial pressure ODE

tauABP

0.001

sec

Time constant for ABP follower
‚àí1

Rtpap

0.1

mmHg sec ml

Rtpad

0.2

mmHg sec ml‚àí1

Distal pulmonary arterial transmural resistance

Rpap

0.0001

mmHg sec ml‚àí1

Proximal pulmonary resistance

0.0299

mmHg sec ml

‚àí1

Distal proximal pulmonary resistance

mmHg sec ml

‚àí1

Pulmonary shunt resistance

mmHg sec ml

‚àí1

Pulmonary arterioles resistance

mmHg sec ml

‚àí1

Pulmonary capillaries resistance

mmHg sec ml

‚àí1

Pulmonary veins resistance

Rpad
Rps
35

Rpa
Rpc
Rpv
Cpap
Cpad
Cpa

4.333
0.057
0.032
0.0001
1.445
2.531
3.102

Proximal pulmonary arterial transmural resistance

ml mmHg

‚àí1

Proximal pulmonary arterial compliance

ml mmHg

‚àí1

Distal pulmonary arterial compliance

ml mmHg

‚àí1

Pulmonary arterioles compliance

‚àí1

Pulmonary capillaries compliance

9.117

ml mmHg

Cpv

52.267

ml mmHg ‚àí1

Pulmonary veins compliance

V pap0

9.81

ml

Proximal pulmonary artery unstressed volume

V pad0

17.16

ml

Distal pulmonary artery unstressed volume

V pa0

17.16

ml

Small pulmonary arteries unstressed volume

V pc0

29.42

ml

Pulmonary capillaries unstressed volume

V pv0

29.597

ml

Lpap

0.00018

Pulmonary veins unstressed volume
2

mmHg sec ml

‚àí1

Proximal arterial inertance

A PREPRINT - J ULY 21, 2020

Cpc

Table 7 continued from previous page
Parameter
Lpad
Rcorepi
Rcorintra
Rcorcap

Value
0.00019
5.285
10.147
4.228

Units

Description
2

mmHg sec ml

‚àí1

Distal pulmonary artery inertance

‚àí

Proximal epicardial arteries resistance

‚àí

Distal epicardial arteries resistance

‚àí

Coronary capillaries resistance

‚àí

s ml 1 mmHg
s ml 1 mmHg
s ml 1 mmHg

36

Rcorvn

1.48

s ml 1 mmHg

Small coronary veins resistance

Ccorepi

0.074

ml/mmHg

Compliance of proximal epicardial arteries

Ccorintra

0.134

ml/mmHg

Compliance of distal epicardial arteries

Ccorcap

0.94

ml/mmHg

Compliance of coronary capillaries

Ccorvn

2.45

ml/mmHg

Compliance of small coronary veins

V corepi0

2.69

ml

Epicardial arteries unstressed volume

V corintra0

2.685

ml

Intramyocardial arteries unstressed volume

V corcap0

2.523

ml

Coronary capillaries unstressed volume

V corvn0

2.493

ml

Coronary veins unstressed volume

a

0.001

sec

Time constant for baroreceptor firing rate

a1

0.036

sec

Time constant for baroreceptor firing rate

a2

0.0018

sec
‚àí1

K

0.991

K_con

1

T _con

10

sec

CNS time parameter for contractility control

l_con

3

sec

CNS time delay for contractility control

a_con

0.299

Time constant for efferent contractility firing

b_con

0.699

Time constant for efferent sympathetic contractility firing

tau_con

0.04
110

K_vaso

1

T _vaso

6

mmHg

Baroreceptor gain (used to account for units)
CNS gain for contractility control

sec
‚àí1

sec

Time parameter for efferent sympathetic contractility firing
Frequency parameter for efferent sympathetic contractility firing
CNS gain for vasomotor tone control

sec

CNS time parameter for vasomotor tone control

A PREPRINT - J ULY 21, 2020

N o_con

sec

Time constant for baroreceptor firing rate
‚àí1

Table 7 continued from previous page
Parameter

Value

Units

Description

l_vaso

3

sec

CNS time delay for vasomotor tone control

a_vaso

‚àí0.466

tau_vaso

0.04

Time constant for efferent vasomotor tone firing
sec

Time parameter for efferent vasomotor tone firing
‚àí1

N o_vaso

110

sec

amin

‚àí2.806

Contractility control offset

bmin

0.699

Contractility control offset

Ka

5

Contractility control scaling factor

Kb

0.5

Contractility control scaling factor

Frequency parameter for efferent vasomotor tone firing

37
A PREPRINT - J ULY 21, 2020

